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Abstract 
Tracing human cancer evolution with hypermutable DNA 
 
Metastasis is the main cause of cancer morbidity and mortality. Despite its clinical 
significance, several fundamental questions about the metastatic process in humans 
remain unsolved. Does metastasis occur early or late in cancer progression? Do 
metastases emanate directly from the primary tumor or give rise to each other? How 
does heterogeneity in the primary tumor relate to the genetic composition of secondary 
lesions? Addressing these questions in representative patient populations is crucial, but 
has been difficult so far. Here we present a simple, scalable PCR assay that enables 
the tracing of tumor lineage in patient tissue specimens. Our methodology relies on 
somatic variation in highly mutable polyguanine (poly-G) repeats located in non-coding 
genomic regions. We show that poly-G mutations are present in a variety of human 
cancers. Using colon carcinoma as an example, we demonstrate an association 
between patient age at diagnosis and tumor mutational burden, suggesting that poly-G 
variants accumulate during normal division in colonic stem cells. We further show that 
poorly differentiated colon carcinomas have fewer mutations than well-differentiated 
tumors, possibly indicating a shorter mitotic history of the founder cell in these cancers. 
We collect multiple spatially separated samples from primary carcinomas and their 
metastases and use poly-G fingerprints to build well-supported phylogenetic trees that 
 iv 
illuminate each patient’s path of progression. Our results imply that levels of intra-tumor 
heterogeneity vary significantly among patients.  
Our approach can generate reliable lineage information in large numbers of 
patients with minimal time and cost expenditure. It can be used in its own right to study 
tumor evolution, or as an efficient screening tool to select samples for deeper analysis 
by next generation sequencing. Further development and successful application of 
targeted cancer therapies will vitally depend on an accurate understanding of clonal 
architecture in human tumors. The mitotic history of a neoplasm, as captured by neutral 
lineage markers, can provide an important backdrop on which to project the distribution 
of hundreds of therapeutically relevant mutations. 
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Chapter 1: Using genetic tools to study metastatic 
progression in humans 
 
 
 
 
Statement of contribution:  Parts of this chapter correspond to a review that is currently 
in preparation. I wrote the manuscript in its entirety.  
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1.1 The importance of intra-tumor heterogeneity in systemic cancer 
After virtual defenselessness in the face of metastatic disease for most of human 
history, a hopeful time has now begun in medicine. Metastasis causes 90% of human 
cancer deaths (Mehlen and Puisieux, 2006), but recent advances in molecularly 
targeted therapies have extended progression-free and overall survival for patients with 
some forms of metastatic cancer. These include BRAF-mutant melanoma (Chapman et 
al., 2011), EGFR-mutant (Maemondo et al., 2010) or ALK-rearranged (Shaw et al., 
2011) lung cancer, EGFR-expressing colon cancer (Cunningham et al., 2004), and most 
gastrointestinal stromal tumors (Reichardt et al., 2012). Concurrent improvements in 
massively parallel sequencing technologies generate a steady stream of putative new 
targets for therapeutic intervention (Ciriello et al., 2013; Kandoth et al., 2013). It could 
be argued that the road toward the eradication of cancer will be straightforward from 
here: more targets will be discovered, novel therapeutics developed, resistance 
(Holohan et al., 2013) will be monitored dynamically and kept in check with precision 
medicine. 
However, increased appreciation of genetic and phenotypic intra-tumor 
heterogeneity casts some doubt on the viability of this simple path forward. The 
emergence of lethal recurrent disease in all patients treated with targeted therapy, 
sometimes within a mere few months, suggests that cells that are inherently treatment 
resistant are invariably present in each tumor. Longitudinal monitoring of the clonal 
composition of tumors before and after treatment confirms the remarkable genetic 
plasticity of cancer (Landau et al., 2013). Even with advanced second-line therapies 
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(potentially consisting of complex drug combinations), it will likely be difficult to bridle the 
evolutionary potential of billions of cancer cells. 
It also remains uncertain whether targeted therapies can successfully be 
transferred from the metastatic to the adjuvant setting (as recently reviewed in Polzer 
and Klein, 2013). While trastuzumab (an anti-HER2 antibody) and imatinib (a c-KIT and 
PDGFR tyrosine kinase inhibitor) have shown benefits as adjuvant therapies in breast 
cancer (Gianni et al., 2011) and gastrointestinal stromal tumors (Reichardt et al., 2012), 
respectively, recent adjuvant trials of EGFR inhibition in lung cancer (Goss et al., 2013) 
and colon cancer (Alberts et al., 2012) have not been encouraging. Genetic and/or 
phenotypic divergence between the primary tumor and minimal residual disease (MRD) 
is suspected to be the root cause of these difficulties (Aguirre-Ghiso et al., 2013). 
Given these pressing clinical challenges, gaining a comprehensive 
understanding of intra-tumor heterogeneity is a central task of translational cancer 
research today. Marked diversity of cancer cells can be observed from a genetic and 
epigenetic perspective, with respect to gene and cell surface marker expression 
patterns, and with reference to differentiation state and propagation potential (Marusyk 
et al., 2012). The umbrella term “intra-tumor heterogeneity” is used 1) to describe 
diversity, as defined by any of the above measures, among cells intermingling in one 
localized tumor area, 2) to refer to differences between spatially distinct tumor regions, 
3) or to denote heterogeneity among multiple non-contiguous lesions in metastatic 
disease. From the point of view of a clinician prescribing targeted therapies, genetic 
divergence between primary tumors, MRD and overt metastasis arguably is the most 
relevant form of intra-tumor diversity. In current practice, molecular analysis of small cell 
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populations from the primary tumor typically guides treatment strategies aimed at the 
eradication of both MRD and macroscopic metastasis. Progressively, however, we are 
becoming aware that genetic targets show discordance both within and between lesions 
(Gerlinger et al., 2012). Re-biopsy of metastases is therefore increasingly being 
advocated (Niikura et al., 2013). While repeat examination of surgically accessible 
metastases of advanced size sometimes is possible (notably always involving the risk of 
pain and infection for the patient), the genetic traits of MRD are far more difficult to test, 
mainly because the relevant cells or microscopic lesions are invisible and potentially 
widely dispersed.  
Since the genetic composition of most metastatic (precursor) lesions cannot be 
analyzed due to these practical limitations, it is becoming increasingly expedient to gain 
a more principled understanding of how diversity arises within the primary tumor and 
how the bottleneck of metastatic dissemination modulates it. Surprisingly, the most 
basic steps of metastasis are still poorly understood. In particular, much uncertainty still 
surrounds the following questions: When do metastatic precursor cells leave the primary 
tumor? The time point of dissemination likely is a major determinant of genetic 
divergence. Also, by what route do metastatic cells spread to form widely disseminated 
disease? For example, do metastases give rise to other metastases or do they emanate 
independently from the primary tumor? An evidence-based model of metastatic 
progression that includes detailed knowledge of factors that shape the genetic 
relationships between primary tumor and metastases would likely improve treatment 
and prevention of advanced disease. Unfortunately, many decisive properties of 
metastasis in humans, among them latency and variable time to recurrence (TTM), are 
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not correctly recapitulated in many animal models (Klein, 2011). Obtaining data in the 
human setting therefore is highly desirable. 
The following part of this chapter describes the theoretical models that currently 
dominate our thinking about metastatic progression and offers definitions of widely used 
concepts in this area. Comparative data of primary tumors and metastases in humans 
will be discussed in the next section, with an emphasis on how the available evidence 
corroborates these models. The chapter concludes with an outline of experimental 
techniques that can used to address the central questions of when and by what route 
systemic disease is established. 
1.2 Models of metastatic progression in humans  
The time course of metastasis varies significantly across different cancer types and 
patients. Metastases can be diagnosed at the same time as the primary tumor 
(synchronous) or after latency periods ranging from a few months to several decades 
(metachronous). The distribution of progression-free survival intervals in the population 
of patients that do relapse is tumor type specific and typically very broad. Currently 
there is no reliable way to predict TTM. While the size of the primary tumor at diagnosis 
correlates with overall risk of metastasis for many cancer types, it is not necessarily an 
indicator of how long the TTM will be. In colon cancer, for example, primary tumor 
characteristics in patients with synchronous vs. metachronous metastases are not 
significantly different (Tsai et al., 2007). 
It appears that individual tumor biology not only controls whether recurrence will 
occur at all, but also determines TTM and how quickly metastatic disease will reach 
lethal dimensions once a cancer has relapsed. The biological mechanisms underlying 
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this large variation are virtually unknown, and many combinations of interacting 
causative elements are conceivable, among them the time point of metastasis relative 
to the evolutionary trajectory of the primary tumor, possible dormancy periods and 
growth rate characteristics at ectopic sites. Several conceptual frameworks exist that 
aim to integrate knowledge of these mechanisms and clinical observations to create a 
“unified theory of metastasis”. As will become apparent below, drastically different 
models of metastatic progression in humans are still competing. This is a reflection of 
how challenging it is to study these processes in vivo and how much research remains 
to be done in this area. 
Linear progression  
The traditional model of metastatic progression is called “linear” because it postulates 
that primary tumor development and metastasis occupy sequential positions on a 
unidirectional timeline of events (Figure 1.1, blue bottom panel). A central assumption of 
linear progression is that only highly aberrant, genetically advanced cancer cells can 
effectively colonize distant organs. These cells are thought to arise in a step-wise 
fashion, through multiple clonal expansions, during the development of the primary 
tumor (Cairns, 1975). Since acquisition of metastasis-enabling mutations is a slow 
process, dissemination typically occurs in late stages of tumorigenesis, around the time 
or shortly before a primary tumor becomes clinically detectable. Consequently, the 
evolutionary divergence between primary and secondary neoplasms is relatively small, 
and the primary tumor is regarded as a good surrogate for the molecular and 
phenotypic properties of metastases. 
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Figure 1.1: Overview of human metastasis models. The cell lineage tree of the 
primary tumor is depicted on the left side. Cells with different genetic alterations are 
indicated in different colors. During the first few divisions after transformation, all cells 
are still genetically similar to each other (red), but as the tumor continues to proliferate 
(dotted lines), diversity increases. Some cells die (X), and expansions of particularly fit 
clones can in turn locally decrease heterogeneity (light blue). Linear progression (blue 
background panel) assumes that late in tumor development, one of these clonal 
expansions gives rise to a metastasis (red connector), which can in turn spawn other 
metastases in a cascade. Parallel progression (green background panel), on the other 
hand, conjectures that metastasis occurs early on and that metastases evolve 
separately from each other and the primary tumor. Under the tumor self-seeding model 
(red background panel), metastatic cells return to their tumor of origin. Finally, 
metastatic precursors may lay dormant for variable time periods (yellow background 
panel).  
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Metastatic cascades 
Loosely associated with the linear progression model, by virtue of placing the 
development of widespread metastasis in the latest stages of carcinogenesis, is the 
conception that metastases, particularly those located in central organs with high blood 
flow such as the lung and liver, give rise to other metastases in a cascading manner 
(Bross et al., 1975). Cascades or “showers of metastases” (Weinberg, 2008) would be 
expected to lead to greater genetic homogeneity of systemic disease than direct 
descent from the primary tumor.  A related, but somewhat distinct potential “cascade 
step” is the lymphatic system. Autopsy studies show that regional and distant lymph 
nodes are by far the most common site of metastasis: at time of death, lymphatic 
lesions are two-fold more frequent than metastases to the liver, which is the next-
common site (Disibio and French, 2008). For many cancer types, the presence of 
cancer cells in regional lymph nodes is a negative prognostic indicator. Historically, it 
was therefore assumed that lymph node metastases are precursors of distant lesions. 
This belief motivated aggressive surgical interventions, such as the radical mastectomy 
and axillary lymph node dissection in breast cancer, to eradicate locoregional disease 
as thoroughly as possible (Fisher, 1980). Axillary lymph node dissection is used much 
less widely today because it does not seem to prolong survival (Giuliano et al., 2011), 
but it is still contentions where lymphatic disease can rise to distant metastases (Klein, 
2013). 
Parallel progression 
Diametrically opposed to linear progression, though not strictly mutually exclusive, is the 
“parallel progression” model (Figure 1.1, green top panel), which posits that metastasis 
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occurs early in cancer development and that primary and secondary tumors evolve 
independently for a significant amount of time (Klein, 2009; 2013). Parallel progression 
assumes that successful dissemination and ectopic survival do not necessarily require a 
complex repertoire of acquired mutations, but can be accomplished by genetically 
inchoate cancer cells with few karyotypic abnormalities. The somatic evolution of these 
early disseminated tumor cells (DTCs) largely happens at distant organ sites and 
involves extensive adaption to local microenvironments. Therefore, substantial genetic 
disparity is expected between the primary tumor and its metastases, as well as between 
metastases in different anatomic locations.  Parallel progression fundamentally doubts 
that molecular profiling of primary tumors is appropriate for selecting effective 
therapeutics against MRD and overtly metastatic disease. 
Tumor self-seeding.  
Both linear and parallel progression models regard metastasis as a unidirectional 
process that begins within the primary neoplasm and terminates at a distant site. 
“Tumor self-seeding” (Figure 1.1, red side panel) is a recently (Kim et al., 2009) 
articulated hypothesis stating that a bilateral, dynamic cell exchange exists between 
synchronous lesions. The primary tumor continually sheds cancer cells into the 
bloodstream, some of which will pass through the lung capillary network to enter the 
arterial circulation. A highly selected subset of these circulating tumor cells (CTCs) re-
enters the original primary site to fuel local progression. Cells that extravasate from 
proliferating metastases could similarly return to the primary tumor. If tumor self-seeding 
indeed took place to a significant degree, it would create genetic links among primary 
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and secondary lesions that would be difficult (or impossible) to distinguish from late 
dissemination. 
Dormancy  
Among the more widely accepted (if unproven) concepts in metastatic progression in 
humans is dormancy (Figure 1.1, yellow bottom panel), a loosely defined term that is 
used to describe multiple distinct forms of tumor growth arrest. In the clinical setting, 
dormancy is invoked to explain “ultra-late” recurrences 10 or more years after resection 
of the primary tumor (Klein, 2011). In cell biological parlance, dormancy can either refer 
to a senescence-like state single disseminated tumor cells enter after they have 
become entrapped in foreign and potentially hostile tissue microenvironments (“tumor 
cell dormancy”) or to the indolent behavior of small subclinical neoplasms which exhibit 
no net growth (“tumor mass dormancy”). Dormancy is an important factor to consider in 
theoretical frameworks of metastasis because it is often impossible to judge whether a 
metastatic lesion appeared after a prolonged latency period because it disseminated 
late in cancer progression or because it underwent a period of dormancy at its new site. 
Conclusion 
The contemporaneous existence of these at times contradictory models illustrates how 
little we still know about metastatic progression in humans. Deepening our 
understanding of how systemic disease emerges has evident implications for future 
therapy development. Personalizing treatment according to the molecular profile of the 
primary tumor is a promising strategy for cancers that follow the linear progression 
model and metastasize in cascades. In the case of parallel progression and dormancy, 
 12 
on the other hand, repeat biopsies or analysis of CTCs or circulating tumor DNA may be 
required to obtain updated information on the genetic constitution of target cells. It is 
possible that disparate modes of metastasis are prevalent in different tumor types, and 
that varying combinations of the “pure” models presented above can occur. The 
following section presents human-derived data on the relationship between primary 
tumors, MRD and overt metastases and discusses the compatibility of the results with 
different models of metastatic progression. 
1.3 Evidence in humans 
Growth kinetics 
A strong line of evidence supporting the parallel progression model is the observation 
that growth rates of primary tumors and metastases are largely similar. It is commonly 
assumed that epithelial cancers develop over many years and even decades (Jones et 
al., 2008; Yachida et al., 2010). If a metastasis is discovered synchronously or just one 
or two years after primary tumor resection – a common event in breast cancer, for 
example (Demicheli et al., 1996) – and its growth rate is comparable to the primary 
tumor, it follows that it must also be many years old (i.e. disseminated early).  Linear 
progression cannot explain the emergence of metastasis close to the time of primary 
tumor diagnosis without assuming dramatically elevated growth rates of secondary 
lesions. However, most imaging studies of metastases suggest that their doubling time 
is similar to the tumor of origin (Klein, 2009). One evident problem with this 
argumentation is that growth rates of subclinical neoplasms cannot be monitored. It 
could be that doubling times of macroscopic metastases are not significantly different 
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from primary tumors, but that their early growth stages are accelerated because tumor 
cells have already acquired proliferation-enabling mutations. Therefore, while tumor 
growth kinetics data seem to favor parallel progression, standing on their own they do 
not constitute proof. 
Circulating and disseminated tumor cells 
More direct evidence can be garnered from comparisons of primary tumors and 
precursors of overt metastases (i.e. MRD). CTCs and DTCs are defined as cytokeratin 
(Meng et al., 2004) or EpCAM-positive (Nagrath et al., 2007) cells found in the blood or 
bone marrow of cancer patients, respectively. Technically, cancer cells lodged in other 
tissues than the bone marrow are also considered DTCs, but only the bone marrow 
lends itself to sampling (and still at a high cost of discomfort to the patient). DTCs are 
significant prognostic biomarkers; their presence is associated with a higher risk of 
relapse in many common epithelial cancers (Riethdorf et al., 2008). CTC numbers, on 
the other hand, are predictive of survival in multiple forms of metastatic cancer 
(Cristofanilli et al., 2004; Danila et al., 2007; Krebs et al., 2011). In a simplified view, 
DTCs can be considered potential precursors of future metastases, while CTCs 
represent an aggregate liquid biopsy of proliferating lesions throughout the body.  
Since they are targets of adjuvant therapy, there has been a long-standing 
interest in the genomics of DTCs. The consensus of many studies in this area is that 
DTCs have fewer genomic aberrations than the corresponding primary tumor (Schardt 
et al., 2005; Schmidt-Kittler et al., 2003; Weckermann et al., 2009). This result 
corroborates the model of parallel progression because it suggests that DTCs left the 
primary tumor in early stages, before more complex genomic aberrations were 
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acquired. Whether the genetic divergence between DTCs and primary tumors can be 
confirmed with high-resolution techniques remains to be determined. Genomic analyses 
of DTCs were often performed with comparative genomic hybridization (CGH) (Klein et 
al., 2002; 1999), a technique with a resolution below 20 megabases (Pinkel et al., 
1998). Many improved technologies for single cell analysis of copy number have since 
become available, e.g. (Navin et al., 2010), and even single cell exome sequencing is 
now feasible (Xu et al., 2012). These methodologies await application to the study of 
DTC genomes. Regardless of analysis technique, one potential caveat when using 
DTCs to estimate the time point of metastasis is the uncertainty whether these cells 
truly are metastatic precursors, or rather represent indolent and thus clinically irrelevant 
remnants of early evolutionary stages of the primary tumor. The most instructive data 
therefore comes from the direct comparison of primary tumors and macroscopic 
metastases. 
Comparative genomics in solid tumors 
Few genome-wide analyses of solid primary tumors and their metastases have been 
conducted thus far, but they are crucial in providing empirical feedback to our models of 
metastatic progression. The primary end goal of existing studies typically has been the 
discovery of mutations that are causative of metastasis. Questions of lineage, i.e. when 
and by what route dissemination occurs and what the phylogenetic relationships 
between multiple tumor cell populations are, often are a secondary concern. It will be 
discussed later why experimental techniques designed for finding metastasis-causing 
mutations are not necessarily appropriate for inferring lineage relationships. 
Nevertheless, the available genome-wide portraits of solid primary tumors and matched 
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metastases represent the most relevant available data for distinguishing between 
different models of progression. Due to their importance, they will be reviewed in detail 
below. 
Close evolutionary ties among primary tumor and metastases 
A study dating to the earlier years of next generation sequencing used an “index lesion” 
approach to compare metastases to their respective primary tumors in 10 colorectal 
cancer patients (Jones et al., 2008). Exonic mutations discovered in the index lesion, 
which was a metastasis in all cases, were evaluated in the primary tumor in a site-
specific manner, i.e. without generating a full exome sequence. 97% were present in 
both neoplasms. These highly convergent results were interpreted in support of linear 
progression. The authors even created a mathematical model to “translate” the mutation 
data into chronological time and estimated that while the development of the primary 
tumor took approximately 25 years, metastasis occurred only 3 years before diagnosis. 
In contrast, an analogously designed study in pancreatic carcinoma (Yachida et 
al., 2010) found substantial genetic divergence. On average, 36% (range 17-52%) of 
mutations present in the metastatic index lesion could not be detected in the primary 
tumor or other metastases. At first glance this result suggested that metastasis in 
pancreatic cancer occurs relatively early. However, the authors went on to sequence 
DNA from multiple distinct regions of the primary tumor and through this spatially 
stratified approach were able to identify areas that had the same mutational profile as 
the index lesion. These “metastatic precursor areas” could be found in both primary 
tumors analyzed in this fashion. The conclusion was that metastatic subclones evolve 
within the primary cancer and give rise to metastases late in tumor progression. 
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It is worth noting here that results from these two studies might be regarded with 
some caution because the index lesion sequencing approach systematically neglects 
the evolutionary trajectory of the primary cancer. All mutations that arise after departure 
of the metastatic clone remain obscure if unbiased variant discovery does not occur in 
both tumors. Due to this limitation, the data observed in these analyses could also be 
explained with a scenario in which the metastatic clone disseminates early, enters a 
period of dormancy during which the mutational profile of the primary tumor at the time 
of departure is “frozen in time”, and finally undergoes a rapid clonal expansion at the 
new site. Since all mutations that the primary tumor acquired while the metastasis was 
dormant would remain invisible, late dissemination could erroneously be concluded. 
In a study of metastatic prostate cancer, all lesions were investigated equally 
comprehensively (Liu et al., 2009). Using comparative genomic hybridization and single 
nucleotide polymorphism (SNP) arrays, the authors compared between two and eight 
synchronous metastases in 24 autopsy cases. They found that samples from the same 
patient typically shared a substantial number of copy number alterations, but also 
discovered subclonal changes. Unfortunately, no quantitative summary of clonal vs. 
subclonal aberrations was given, and no phylogenetic reconstruction was attempted: 
the magnitude of genomic discordance between metastases therefore remained 
somewhat unclear. A further limitation was that the primary tumor was available for 
comparison in 5 subjects only. In those cases, the authors reported “no signficant 
difference” between the primary tumor and its metastases, a finding that would appear 
to support the linear progression model in the setting of metastatic prostate cancer. 
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Notably, no specific genetic adaptation of metastases to ectopic microenvironments in 
different organs – a central prediction of parallel progression – was observed. 
That tumor cell populations can thrive in dramatically different microenvironments 
without undergoing significant genetic adaptation was further shown in a metastatic 
triple-negative breast carcinoma (Ding et al., 2010). Ding et al. sequenced the whole 
genome of the primary breast tumor (post neoadjuvant chemotherapy), a pre-treatment 
biopsy that was propagated as a xenograft, and a matched cerebellar metastasis. 48 
out of 50 discovered somatic mutations were present in all three tumors, indicating no 
significant genetic divergence. Interestingly, the allele frequencies of these mutations 
were broadly distributed in the primary tumor (ranging from <10% to 89%), while a 
heterogeneity reduction took place in the metastasis and the xenograft, with more than 
50% of mutations showing enrichment in both these samples. This similar enrichment 
pattern showed that competing for survival in an ectopic microenvironment (regardless 
of whether this environment is the cerebellum or a mouse organism) can select for the 
same set of tumor-propagating cells. Notably, chemotherapeutic intervention did not 
seem to affect this shared clonal composition much. In both samples, the narrowing of 
the mutant allele frequency distribution was not accompanied by outright loss of any 
mutations, raising the possibility that the cerebellar metastasis – like the xenograft – 
was seeded by more than one cell from the primary tumor (polyclonal metastasis). 
In contrast, a single cell sequencing study of a triple-negative breast carcinoma 
and its liver metastasis concluded that metastasis was monoclonal. Navin et al. 
compared genome-wide copy number alterations of 100 individual cells derived from the 
two lesions (Navin et al., 2011). Cells from the metastasis and the primary tumor were 
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very similar to each other, but separated into two distinct branches in an unsupervised 
neighbor-joining analysis. This indicated that one cell from the dominant clonal 
population of the primary tumor had founded the metastasis and that since then, no 
further mingling had taken place. Again these results were considered to be indicative of 
linear progression and late dissemination. 
Genetic divergence among primary tumor and metastases 
Relatively few genome-wide studies have found substantial genetic divergence between 
primary tumor and metastases. In one prominent example, an index lesion sequencing 
approach was used to compare the mutational spectrum of a pleural effusion metastasis 
and its primary tumor, a lobular breast carcinoma that was resected 9 years earlier 
(Shah et al., 2009). In contrast to the findings in pancreatic and colorectal cancer, only 
11 of the 32 mutations that were discovered in the metastasis were also present in the 
primary tumor, indicating independent somatic evolution of the metastatic clone. 
Whether this result can be regarded as evidence of parallel progression is very 
debatable, given the long latency of 9 years. If the primary tumor had been sequenced 
as well, more rigorous conclusions could be drawn. For example, early dissemination 
would be a possibility if a large number of mutations that were present in the primary 
tumor could not be found in the metastasis. However, the more limited approach taken 
in this study is understandable given that sequencing costs at the time were significantly 
higher than today. 
A more recent, very influential case study in renal cell carcinoma also found 
extensive differences between primary tumor and metastases (Gerlinger et al., 2012). In 
a thoughtful experimental design, Gerlinger et al. sequenced the exomes of nine 
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spatially distinct portions of a primary renal clear cell tumor, two synchronous 
metastases, and two pre-treatment biopsies. The data allowed for several important 
observations: 1) The evolutionary branches of primary and metastatic clones had 
diverged early on. Since the split, they had evolved at comparable rates, as shown by 
an almost identical number of metastasis-specific (n=28) and primary-specific (n=31) 
mutations. 2) A discrete region in the primary tumor harbored a precursor of the 
metastatic clone that contained some, but not all of the metastasis-specific mutations. 3) 
Pre-treatment biopsies of the primary tumor and the metastasis clustered with their 
post-treatment counterparts, suggesting that treatment with everolimus had not 
significantly affected clonal compositions. Taken together, the results in this renal cell 
carcinoma favor parallel progression of primary tumor and metastases. 
Smaller-scale comparative genetics 
While high-resolution genome- or exome-scale comparisons of primary tumors and 
metastases are still rare, hundreds such studies have been conducted using more 
limited marker panels or low-resolution metaphase CGH. Patient numbers in these 
studies are typically higher than in the genome-wide analyses summarized above, and 
cases supporting linear and parallel progression are usually found in varying proportions 
in the same study. Thought-provoking examples are: deep sequencing of a “cancer 
mini-genome” in primary colorectal cancers and matched metachronous liver 
metastases demonstrating that the number of concordant mutations vastly differs 
among patients (Vermaat et al., 2012); a CGH analysis of primary breast carcinomas 
and matched metachronous metastases demonstrating close clonal relationships in 
69%, and almost completely unrelated genomic changes in 31% of patients 
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(Kuukasjarvi et al., 1997); finally, reports of varying frequencies of discordant mutations 
in therapeutically or prognostically important genes in lung adenocarcinoma (Schmid et 
al., 2009), melanoma (Colombino et al., 2012), colorectal (Baldus et al., 2010), and 
breast cancer (Niikura et al., 2013). Many more examples can be found in an excellent 
review by Stoecklein and Klein (Stoecklein and Klein, 2009).  
Evidence in humans: lessons learned  
The eclectic results presented above illustrate that we have yet to arrive at a definitive 
and coherent picture of metastasis in humans. With respect to the rival hypotheses of 
linear and parallel progression, the jury is still out on which model will prevail in the long 
run. It is likely that we will need both frameworks to describe metastasis in different 
cancer types and clinical scenarios.  
Going forward, future genomics studies that aim to infer timelines of metastasis 
from sequence data should consider the following points. First, it will be germane to 
provide a detailed clinical context (patient age, anatomic location and extent of disease, 
treatment history etc.) for all analyzed samples. Current studies often omit this critical 
information and thus render meaningful comparisons with prior data impossible. How 
advanced a cancer is and how aggressively it developed likely is significantly 
associated with the shape of its genetic landscape. For example, as far as can be 
inferred from the provided clinical information, most findings of genetic concordance 
between primary tumor and metastases were obtained in patients who underwent 
extensive treatment and rapidly succumbed to aggressive disease. These samples are 
often easier to obtain than metachronous metastases, but probably do not accurately 
represent what happens in patients with more indolent cancers. 
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Second, a well-defined theoretical framework for the interpretation and 
comparison of results from different studies should be established. One example of 
potential misinformation arising in the absence of such a framework is widespread 
neglect of what could be termed the “founder effect” (illustrated in Figure 1.2). In current 
practice, the number of alterations that differ between two cancerous lesions is 
reported, and subjectively judged to be “large” or “small”, sometimes implicitly and often 
explicitly in relation to the number of overall detected changes. This may lead to 
misleading results as the number of mutations common to all cells within a tumor may 
vary widely depending on the mitotic history of the tumor founder cell. The mutational 
burden of any normal cell continually increases as it divides over a patient’s lifetime. 
Current estimates are that at least 50% (Tomasetti et al., 2013) or more (Welch et al., 
2012) of the mutations found in a cancer represent the “fossil record” of the cell division 
history of the tumor founder cell. Depending on how frequently the founder cell divided, 
alterations that accumulated during carcinogenesis may represent different fractions of 
the total, even if tumors evolved exactly equally otherwise. These effects should be 
taken into consideration when inferring timelines of metastasis from genetic distances. 
Gaining a greater understanding of mutation prevalence in normal cells located in 
different human tissues will be crucial in this regard. 
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Figure 1.2: Founder Effect. (A) A tumor mass arising from a mitotically young founder 
cell will have fewer clonal mutations than (B) a tumor arising from a mitotically 
advanced cell. The numbers of subclonal “progressor mutations” acquired during tumor 
development may appear large or small in comparison with the number of founder 
mutations. 
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It will furthermore be important to determine whether tumor self-seeding plays a 
role in human disease because a substantial dynamic exchange of cells between 
synchronous lesions would make genetic reconstruction of tumor history very 
challenging. Tumor self-seeding seems to be a plausible explanation for some 
phenomena observed in genome-wide comparisons. For example, in cases in which a 
small localized patch in the primary tumor corresponds to a distant lesion (Yachida et 
al., 2010), but is distinct from the dominant clone in the primary, retrograde metastasis 
may be a more parsimonious explanation then late metastasis of small subclone. We 
know that gene expression profiles of bulk tumor tissue predict the risk of metastasis 
(van 't Veer et al., 2002). This finding is difficult to reconcile with metastatic properties 
confined to a very small portion of cells in the primary tumor. The tumor-self seeding 
model predicts that returning “seeds” will be more likely to inhabit the surface regions of 
the primary tumor (Comen et al., 2011). Detailed geographical analysis could elucidate 
whether this is the case in human tumors. If self-seeding does indeed occur at a 
significant level, we cannot hope to discover genetic variants that are required for early 
adaptation to specific microenvironments – an important prediction of parallel 
progression – in late stage disease. 
1.4 Studying the metastatic lineage in humans: experimental approaches 
The preceding parts have laid forward the motivations for studying the evolution of 
metastases and further refining our disease models. Here, a brief overview of 
experimental approaches toward this goal and their respective advantages and 
disadvantages will be presented. At the outset, a few conceptual considerations might 
be helpful. The primary aim of most comparative genetics studies, including those 
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reviewed above, is to identify alterations with functional significance. The hope is that 
these “drivers” or causal variants will help explain why metastases arise, and thereby 
inspire new treatment strategies. Resolving the conflict between the competing 
hypotheses of linear and parallel progression, on the other hand, will require 
determining which cells metastasize, by what routes, at what point in time: uncovering 
what happens when. These are fundamentally questions of tumor lineage or tumor 
phylogeny. Reflections on lineage are often appended to analyses designed to discover 
driver mutations, but in fact the questions of why vs. what/when are preferably 
addressed with different strategies. The first part of this section will discuss approaches 
that have been used in tumor lineage tracing, but were not specifically designed for this 
purpose (“Reappropriated methods”). An overview of methods that were exclusively 
developed to achieve accurate phylogenetic reconstruction in cancer (“Proper 
phylogenetic markers”) will follow. 
Reappropriated methods 
Histopathology 
Inspection of a cancer’s histopathology is a critical step in determining prognosis and 
treatment. It is also the oldest and still most widely used method for lineage 
determination. Even in modern, molecular biology empowered clinical practice, a 
pathologist uses morphological examination to decide whether a malignancy is a 
metastasis or a new primary process, such as in multifocal lung or breast cancer. 
Treatment courses and prognostication can vary widely based on the outcome. The 
advantage of this “lineage tracing by eye” is mainly its convenience. However, 
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morphological comparison may not always reliably determine common descent. An 
interesting historical example is that Rudolf Virchow, the “father of cellular pathology”, 
firmly believed for a majority of his scientific career that primary tumors and metastases 
arise independently. He suspected that the primary cancer infuses the blood with 
“toxins” that trigger the formation of secondary growths at distant sites, but that no 
cellular exchange takes place (Weiss, 2000). The modern pathologist appears to be 
inversely biased: in a morphological evaluation of lung squamous cell carcinoma 
following head and neck squamous cell carcinoma, 86% of cases were diagnosed as 
metastases, while a molecular assay based on loss of heterozygosity (LOH) indicated 
that in fact only 43% were related lesions, and the rest represented independent 
transformations (Geurts et al., 2005). Also, some tumors can undergo profound 
histological changes in response to treatment (Sequist et al., 2011). Therefore, if 
alternatives are available, tumor morphology is not a preferred method for lineage 
tracing.  
Chromosomal alterations 
A rich literature documents the use of chromosomal alterations to study clonal 
relationships in metastatic cancer. Genome-wide approaches include metaphase CGH, 
its high-resolution variant arrayCGH and SNP microarrays. The most comprehensive 
view of chromosomal aberrations, including balanced translocations and inversions, can 
be inferred from deep paired-end sequencing, but almost no such data exists for 
primary tumors and matched metastases. Commonly used locus-specific techniques 
are LOH analysis of polymorphic DNA sequences and fluorescence in situ hybridization 
(FISH). Chromosomal alterations can be detected relatively easily and occur frequently 
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in many cancer types. However, it is debatable whether they represent good lineage 
markers because many if not most large-scale rearrangements are likely to have strong 
selective effects (Davoli et al., 2013). Convergent evolution, the independent 
occurrence of similar alteration patterns in two phylogenetically unrelated cells, cannot 
be excluded unless breakpoints are mapped very finely. For example, amplifications of 
chromosome 7 and deletions of chromosome 10 are present in more than 80% of 
primary glioblastomas (Beroukhim et al., 2007), even though they are obviously not 
related by descent. Some chromosomal alterations that are typically regarded as rare 
stochastic events can be induced by endogenous stimuli, such as the sharp increase of 
gene fusions between TMPRSS2 and ERG upon dihydrotestosterone exposure in 
prostate cancer cells (Mani et al., 2009). Finally, our incomplete understanding of how 
the number of chromosomal alterations relates to mitotic distance poses a problem. It is 
thought that the total burden of somatic mutations in a cell’s genome is correlated with 
the number of divisions it underwent since fertilization (Welch et al., 2012). Hence, 
genetic divergence between two lesions as measured by single nucleotide variants 
(SNVs) can arguably be related to the number of mitoses that occurred since their 
separation. No such correlation is known for copy number variants (CNVs). For 
example, it was repeatedly reported that neurons, which are not a mitotically active 
tissue, are particularly enriched for CNVs (McConnell et al., 2013; Yurov et al., 2007). It 
seems that developmental and/or environmental factors influence CNVs in ways we do 
not yet fully appreciate. Chromosomal alterations should therefore be used with caution 
for inference of tumor phylogenetics. 
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Genome- or exome-wide somatic mutations 
The problem of selective forces potentially causing artifacts in lineage reconstruction 
does not only arise with chromosomal alterations, but also with exome sequences. The 
exome is the 1% of the genome that is under most intensive evolutionary pressure and 
therefore arguably one of the least suitable targets for lineage analysis. Analogous 
emergence (or disappearance) of somatic variants could easily be misinterpreted as 
homology. The magnitude of this issue probably depends on the number of divergent 
mutations. If several dozens of variants are found that differ between primary tumor and 
metastases, such as in renal cell carcinoma (Gerlinger et al., 2012), many of them are 
likely to be neutral and reflect lineage relationships correctly. If limited divergent 
mutations are found – e.g. in a hypothetical scenario in which only a couple of mutations 
(perhaps even in cancer-related genes) are shared by multiple metastases, but not by 
the primary tumor – convergent evolution becomes a realistic concern. Ideally, the 
whole genome would be sequenced in all samples of interest: neutral intergenic regions 
could be used for lineage analysis, and functionally relevant information could be 
gleaned from SNVs, CNVs, and other structural variants. The (probably temporary) 
disadvantage is that whole genome sequencing of multiple tumor specimens in large 
numbers of patients still puts significant strain on financial and data analysis resources.  
Proper phylogenetic markers 
A molecular phylogenetic marker suitable for somatic lineage tracing should have 
several properties: First, it should be selectively neutral. Second, it should mutate at a 
high rate. Third, acquisition of mutations should occur during cell division so that total 
mutational burden measured in any cell is proportional to the number of cell divisions it 
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underwent since the zygote.  The following section will present some phylogenetic 
markers that are compatible with some or all of these demands and thus appropriate for 
lineage analysis in cancer. 
Epigenetic markers 
Epigenetic modifications have a long history of being used as lineage markers. X 
inactivation, the random silencing of one X chromosome in females during early 
embryonic development, has been particularly useful in the study of tumor lineages. In 
normal tissues, both X chromosomes are inactivated in similar proportions. In 1965, 
Linder and Gartler discovered that in leiomyomas, all cells show inactivation of the 
same X chromosome, providing the first proof of monoclonality in tumors (Linder and 
Gartler, 1965). Since then, X inactivation has been used extensively to test clonality 
both within a tumor mass (Going et al., 2001) and between different lesions (Katona et 
al., 2007; Kuukasjarvi et al., 1997). X inactivation fulfills the first criteria of a good 
lineage marker because it is a random and presumably neutral event; in most tissues 
analyzed in bulk, the ratio between silenced alleles is indeed about 1:1, arguing against 
strong selective effects (Novelli et al., 2003). A further advantage is that silencing is 
stably heritable and unchanging: therefore, if two cell populations do not share the same 
X chromosome inactivation pattern, it can safely be concluded that they did not intermix 
since embryogenesis. However, the static nature of the marker is also its greatest 
limitation, because it cannot provide any information on evolutionary events that 
occurred after transformation of a tumor founder cell. Moreover, while a discordant 
pattern of X chromosome inactivation in two lesions is strong evidence of independent 
lineages, a concordant pattern can arise with a probability of 50% even if cell 
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populations are unrelated, fundamentally limiting the resolution of the assay. It therefore 
does not comply with the two latter characteristics of a good somatic lineage marker: 
high mutation rate and correlation of alterations with cell division history. 
Methylation analysis of CpG dinucleotides fulfills these criteria. A majority of CpG 
loci are unmethylated in early development and acquire heritable cytosine methylation 
marks with successive rounds of cell division at a rate that is several orders of 
magnitude higher than the somatic nucleotide substitution rate (Shibata and Tavaré, 
2006). Neutrality can be assumed when CpG loci in promoters of genes that are not 
expressed in the tissue of interest (e.g. heart-specific loci like CSX in colonic tissue) are 
examined. At least theoretically, CpG methylation represents an ideal somatic 
“molecular clock” (Shibata et al., 1996) and has been used extensively to study stem 
cell (Nicolas et al., 2007; Yatabe et al., 2001) and tumor (Siegmund et al., 2011; 2009; 
Woo et al., 2009) lineages in humans. However, an important concern is that cytosine 
methylation is a reversible mark and could potentially be affected by genome-wide 
methylation changes that occur during tumorigenesis (Feinberg and Vogelstein, 1983). 
A permanent change in DNA sequence would therefore be preferable to methylation for 
purposes of lineage tracing. 
Microsatellites 
Microsatellite sequences arguably come as close as possible to being optimal somatic 
lineage markers. Also called short tandem or simple sequence repeats, they are 
consecutive repetitions of one to four base pair units that are vastly overrepresented in 
the genome. Most are non-coding and show high levels of polymorphism in the 
population (Ellegren, 2004). Mutations typically occur in the form of insertion or deletion 
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of one or multiple units through slippage of DNA polymerase (Strand et al., 1993) and 
are thus tightly coupled to cell division. Mutation rates vary depending on the size and 
length of the repeat, but are generally much higher than the average genome-wide 
mutation rate, which is estimated to be approximately 10-9 per base per division in 
humans (Lynch, 2010). Across unique sequence, this number can vary to a limited 
degree (approximately five-fold according to recent estimates (Lawrence et al., 2013)). 
By contrast, the mutation rate of a typical (CA)17 dinucleotide repeat in human cells is 
100-times higher, on the order of 10-7 (Boyer et al., 2002). 
Microsatellites first entered the spotlight in cancer genetics when frequent 
somatic length polymorphisms in these sequences were found in familial colorectal 
cancers (Aaltonen et al., 1993; Ionov et al., 1993) in patients with Lynch syndrome, also 
known as hereditary non-polyposis coli (HNPCC). The phenomenon, coined 
“microsatellite instability” (MSI), could also be observed in 10-15% of sporadic colorectal 
cancers and was associated with an improved prognosis (Samowitz et al., 2001). It was 
later discovered that MSI was associated with germline (HNPCC) or somatic (sporadic 
cases) mutations in DNA mismatch repair genes MLH1, MSH2, MSH6 or PMS2 
(Bonadona et al., 2011; Fishel et al., 1993).  
Microsatellites were subsequently used as “molecular clocks” of tumor evolution 
in MSI+ human cancers. Shibata and colleagues showed that dinucleotide repeat length 
distributions vary across tumor regions in HNPCC patients and suggested that 
heterogeneity is related to mitotic age, with older regions displaying more diversity 
(Shibata et al., 1996). Interestingly, they found similar mitotic ages in adenomas and 
carcinomas (Tsao et al., 2000). Randomly occurring replication slippage mutations were 
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used to reconstruct the phylogenetic relationships between single cells in MMR-deficient 
Mlh1+/- mice, both in normal tissues (Reizel et al., 2011; 2012; Wasserstrom et al., 
2008) and a spontaneously arising lymphoma (Frumkin et al., 2008). While these 
studies attested to the power of somatic microsatellite alterations for phylogenetic 
inference, mutation rates of most simple repeats in MMR-proficient cells are too low to 
make this approach generalizable to normal tissues and microsatellite stable tumors.  
In 2006, Salipante and Horwitz introduced a novel methodology for somatic 
lineage tracing that relied on a class of particularly mutable guanine mononucleotide 
repeats (Salipante and Horwitz, 2006). Polyguanine (poly-G) tracts are abundant in the 
human genome (Table 1.1) and can reach mutation rates of 10-6 per base per division in 
human cells (Boyer et al., 2002).; they mutate approximately 100 times faster than 
dinucleotide repeats  and 1000 times faster than unique sequence. By genotyping 
merely 28 poly-G loci, the correct phylogenetic relationships between cells evolving in 
vitro for 66 divisions could be determined (Salipante and Horwitz, 2006). The technique 
was subsequently used to study various aspects of murine development in MMR-
proficient animals (Salipante et al., 2010; 2008; Salk and Horwitz, 2010; Zhou et al., 
2013). Importantly, poly-G analysis was also shown to be applicable in the human 
setting when pre-neoplastic clonal expansions marked by poly-G mutations were 
identified as a prodrome of cancer development in ulcerative colitis patients (Salk et al., 
2009).  
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Table 1.1: Overview of poly-G tracts in the human genome (Hg19). Based on 
custom sequence analysis. 
 
Total # of poly-G tracts (>10 bp)  9106 
In introns 4781 
Overlapping exons 296 
Overlapping CpG islands 416 
Intergenic, no CpG islands 4141 
 
1.5 Research aims 
The research presented in this dissertation shows how somatic mutations in 
hypermutable poly-G tracts can be used to reconstruct phylogenetic relationships in 
human cancer. The work was motivated by the many pressing questions that still 
surround the development of metastatic disease. While numerous large-scale, multi-
institutional efforts to characterize causal variants in the cancer genome are underway, 
we still need to improve our understanding of the fundamental steps of metastatic 
progression in humans. In particular, it remains unclear when and by what route cancer 
cells spread throughout the organism. At the inception of this project, I extensively 
searched the literature for a methodology that would enable construction of “pedigrees” 
of tumor cell populations in human samples. Among the many available technologies, 
genotyping of poly-G tracts appeared to be the optimal solution: it allowed for 
quantitative as opposed to merely qualitative analysis; it was (at least theoretically) 
applicable to archival formalin fixed and paraffin embedded tissue specimens; it was 
scalable and cost-effective and thus well-suited for analysis of large numbers of 
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samples. In the following chapter, I will describe how I adapted poly-G tract profiling for 
the study of metastasis in human colorectal cancer. 
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2.1 Abstract 
Intra-tumor heterogeneity in metastatic cancer influences treatment outcomes but has 
not been assessed in representative patient populations. Here we report that a simple 
PCR-based assay interrogating somatic variation in hypermutable polyguanine repeats 
can be used to study clonal architecture in human cancer. We find that 91% of tumors in 
a cohort of 22 colon carcinoma patients contain polyguanine variants. Mutation load 
positively correlates with patient age and inversely correlates with histological grade. 
We generate polyguanine mutation profiles of spatially separated samples from primary 
carcinomas and matched metastases to build well-supported phylogenetic trees that 
illuminate individual patient’s path of progression. Our results show varying degrees of 
intra-tumor heterogeneity in different patients and suggest that metastasis occurs late in 
colon cancer development.  
2.2 Significance 
Genetic heterogeneity in systemic cancer is of great clinical interest because it impacts 
therapeutic response and reflects how tumor cells grow and spread. We present a 
methodology that enables efficient evaluation of intra-tumor heterogeneity in patients 
through analysis of neutral somatic variation hotspots. Using only 20 genomic markers, 
we demonstrate a unique pattern of clonal diversity in each patient. Some tumors are 
significantly more diversified than others. Our data suggest that metastasis in colon 
cancer is a late event and indicate that distinct clones can give rise to lymphatic and 
distant metastases. Our methodology is applicable to other human cancer types and 
facilitates high-throughput investigation of tumor evolution. 
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2.3 Introduction 
Human cancers are composed of a continually evolving population of genetically and 
phenotypically divergent cells (Marusyk et al., 2012). This reservoir of diversity feeds 
the natural selection process that fundamentally drives disease progression through 
acquisition of metastatic properties and emergence of therapy-resistant clones (Fidler, 
2003; Greaves and Maley, 2012; Merlo et al., 2006). In recent years, characterization of 
intra-tumor heterogeneity has received increased attention as advanced sequencing 
technologies have enabled more detailed analysis of tumor cell populations (Anderson 
et al., 2011; Ding et al., 2010; Gerlinger et al., 2012; Yachida et al., 2010).  
Depending on the context, the term “intra-tumor heterogeneity” refers either to 
differences between cells that coexist in one localized tumor region, or to variation in 
clonal composition between spatially separated parts, most notably between a primary 
tumor and its metastases. The extent of genetic divergence between primary and 
metastatic tumors (and the history of dissemination encoded therein) is beginning to be 
investigated, but relatively few patient data are currently available. The canonical ‘linear 
progression’ model of metastasis states that a genetically advanced cell metastasizes 
late in primary tumor development (Klein, 2008; 2009; Weinberg, 2007). This 
aggressive clone generates new metastases in a so-called ‘metastasis shower’ 
(Weinberg, 2008). Linear progression predicts metastases will be genetically similar to 
the primary tumor and to each other. The alternative ‘parallel progression’ model (Klein, 
2009) posits that metastasis occurs early in tumor evolution and consequently expects 
metastases to be substantially different from one another, and from the primary tumor, 
because they evolve separately over long periods of time. As more data become 
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available, both scenarios can likely be corroborated. Importantly, different modes of 
metastasis may be prevalent in different cancer types. For example, studies of 
pancreatic adenocarcinoma (Yachida et al., 2010) and triple negative breast cancer 
(Ding et al., 2010) demonstrated that the primary tumor and its metastases share a 
majority of mutations, thereby indicating late dissemination. A recent comparative 
sequencing study in renal cell carcinoma, on the other hand, found substantial genetic 
divergence among primary and metastatic tumors (Gerlinger et al., 2012). Notably, 
however, two metastases in distinct anatomical locations were almost identical to one 
another, suggesting a common founder clone related to a spatially discrete portion of 
the primary tumor. This example highlights how studying intra-tumor heterogeneity and 
mitotic history can reveal the evolution of systemic disease. Many clinically relevant 
questions in this area remain unanswered. Are highly diversified primary tumors more 
likely to give rise to genetically heterogeneous metastases? How does genetic diversity 
affect response to therapy? Heterogeneity is thought to increase resistance to therapy 
(Shibata, 2012). Metastases appear to be more homogeneous than primary tumors (Liu 
et al., 2009) – how does this affect their therapy response? 
Addressing these important questions about the evolution of metastatic cancer 
will require analyzing large numbers of patients with different types of tumors. Ideally, 
whole genome or exome sequencing would be performed on multiple specimens from 
each patient. With sequencing capacities continually rising, this approach will likely 
become feasible in the future. Presently, though, only large genome centers can 
regularly generate and process data sets of this magnitude. To study intra-tumor 
heterogeneity more efficiently, and therefore more widely, it would be expedient to 
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target selected regions of the tumor genome that are enriched for somatic variation. 
Genes frequently altered in cancer are an option, but since driver mutations affect 
competitive advantage, their distribution may not reflect the correct phylogenetic 
relationships among tumor cell populations. Accurate reconstruction of cell division and 
migration events that occurred during tumor evolution can also be achieved with neutral 
genetic markers. Short repeats (microsatellites) in non-coding regions are especially 
suited for this purpose. Due to replication slippage (Viguera et al., 2001), mutations are 
introduced frequently but presumably have no effect on fitness. In patients with DNA 
mismatch repair (MMR) defects and resulting microsatellite instability, variation in 
dinucleotide repeats has been used to study several aspects of tumor progression 
(Shibata et al., 1996; Tsao et al., 2000; 1998), but mutation rates in tumors with intact 
MMR are too low to make this approach widely applicable (Laiho et al., 2002).   
Recent research identified a particularly mutable class of polyguanine (poly-G) 
mononucleotide repeats as a hotspot of somatic variation even in normal cells 
(Salipante and Horwitz, 2006). Analysis of poly-G repeats has successfully been used 
to study phylogenetic relationships between single cells in mouse development 
(Salipante et al., 2010; 2008; Zhou et al., 2013) and has been adapted for detecting 
preneoplastic clonal expansions in ulcerative colitis patients (Salk et al., 2009).  
Here we show that analysis of poly-G repeats can determine lineage 
relationships in human cancer. We analyze a cohort of 22 colon cancer patients and 
find that most tumors contain an abundance of poly-G variants. We use poly-G mutation 
profiles to build well-supported phylogenetic trees that show ancestral relationships 
between primary tumors and their metastases. Our work, in accordance with previous 
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studies (Jones et al., 2008), suggests that metastasis in colon cancer is a late event and 
demonstrates how a simple and highly scalable assay can be used to generate reliable 
maps of clonal architecture in formalin fixed and paraffin embedded (FFPE) tumor 
samples.  
2.4 Results 
Polyguanine tracts encode tumor lineage 
We began by screening a cohort of 22 human colon cancers for somatic mutations in a 
panel of 20 poly-G tracts. Insertions/deletions of one or more base pairs in poly-G runs 
are a byproduct of normal replication. Human DNA polymerase replicates unique 
sequences with high fidelity, but replication accuracy significantly decreases in short 
tandem repeats (Ellegren, 2004; Weber and Wong, 1993). Guanine homopolymers are 
particularly prone to replication slippage errors and can have mutation frequencies as 
high as 10-4 per base per cell division (Boyer et al., 2002). Figure 1 illustrates 
schematically how poly-G variants accumulate in genetic lineages as the zygote divides 
to give rise to the trillions of cells that constitute the adult human. A given poly-G tract 
has a certain probability of undergoing an insertion or deletion mutation during each 
division. This probability depends on a variety of factors, including the composition of 
the sequence surrounding the poly-G tract (Ellegren, 2004), and generally increases 
with repeat length (Brinkmann et al., 1998).  
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Figure 2.1: Propagation of neutral poly-G mutations in somatic cell lineages. 
Schematic representation. The vector (0000) represents the genotype of the zygote at 
four hypothetical poly-G alleles. During each cell division, an allele has a defined 
probability of undergoing a length alteration, noted as -1 for a deletion and +1 for an 
insertion. As cells divide and acquire mutations during development, extensive mixing 
occurs (black arrows between tree branches). As a result, mature tissues consist of 
cells that are derived from all branches of the tree, all harboring distinct mutational 
profiles. When a sample of normal tissue is analyzed, a majority of cells will not be 
mutated at any given locus, and the sample will have the zygote genotype (blue bar 
symbolizing cell composition of normal tissue sample). During tumorigenesis, the clonal 
expansion of one founder cell leads to a locally confined population of cells that all 
share its genotype (red bar) and can thus be differentiated from the zygote genotype. 
The founding of a monoclonal metastasis (green bar) is analogous. The right side 
shows examples of poly-G stutter distributions for marker Sal45 for normal tissue, a 
primary colon cancer, and a metastasis to the ovary. 
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encodes its cell division history and its location in the organism’s “cell lineage tree” 
(Frumkin et al., 2008; 2005; Wasserstrom et al., 2008a). If single cells were isolated and 
their genomes individually analyzed, it would be possible to reconstruct the phylogenetic 
relationships between them, as has been demonstrated in murine development 
(Salipante et al., 2010) and cell culture (Salipante and Horwitz, 2006) using poly-G 
tracts, other microsatellites (Frumkin et al., 2008; Wasserstrom et al., 2008a), or 
random genomic regions (Carlson et al., 2012) as lineage markers.  
The primary drawback of this approach is that it can be very challenging to 
expand single cells from normal tissue to generate sufficient material for sequence 
analysis, and whole genome amplification can introduce artifacts for which it is difficult 
to control. In bulk tissue analysis, on the other hand, the genomes of hundreds of 
thousands or millions of cells from divergent genetic lineages are combined in one 
sample and the mutational profile of any single cell is rendered undetectable. Even in 
relatively homogeneous tissues, such as the liver parenchyma, cells derive from many 
different branches of the cell lineage tree because extensive mixing occurs during 
development (Salipante et al., 2010). The result is that at any given locus, most cells will 
not be mutated. Analyzing a bulk tissue sample therefore yields the genotype of the 
most recent common ancestor of all cells, i.e. the zygote or “germline” genotype in the 
case of normal tissue (Salk and Horwitz, 2010).  
A fundamentally different scenario arises during carcinogenesis, as one 
transformed cell begins to proliferate and create a locally confined population of 
daughter cells that are all closely related to each other. Sampling this population will 
reveal the genotype of the most recent common ancestor – the tumor founder cell. As 
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the tumor grows, it accumulates new mutations that may in turn rise above the “white 
noise” of genetic diversity if a clone becomes locally dominant or metastasizes to form a 
colony of homogeneous progeny at a distant site. Phylogenetic analysis relying on bulk 
tissue samples is therefore uniquely possible in cancer because clonal expansions 
unmask genetic variants that can be used to trace lineage. The rightmost panel of 
Figure 2.1 shows examples of poly-G tract genotypes in normal (polyclonal) human 
tissue, a primary tumor, and its metastasis. Since poly-G tracts are inherently 
hypermutable, Taq polymerase slippage during PCR generates a fragment distribution 
instead of a single product. This fragment distribution can be precisely quantified, at 
single base pair resolution, by capillary electrophoresis following PCR with fluorescent 
primers. The distribution mode represents the “true” genotype. If a tumor sample stutter 
pattern shifts from the normal reference derived from the same patient, then that sample 
contains new mutated alleles. We sought to determine whether mutations in poly-G 
sequences could be found in human colon cancer patients. 
Polyguanine mutations are present in most colon cancers. 
The 22 cases in our cohort were randomly selected from all patients who underwent 
colectomy and received a diagnosis of invasive carcinoma at Massachusetts General 
Hospital between 2010 and 2011. Complete patient information (pathological diagnosis, 
tumor size, histological grade, stage, anatomic location of the tumor, neoadjuvant 
therapy etc.) is presented in Supplementary Table S1. Since our ultimate goal was to 
study metastatic progression, we further sub-selected patients who had at least 3 lymph 
node metastases and/or distant metastases. Next, we screened matched pairs of 
primary tumor and normal tissue for poly-G variants at 20 genomic loci. DNA was 
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extracted from formalin-fixed paraffin-embedded tissue cores and subjected to poly-G 
tract profiling. Mutated alleles were found in 91% of patients (Fig. 2.2A; complete 
genotype information in Supplementary Tables S2-S6). As expected, colon cancers with 
microsatellite instability (MSI) harbored the most alterations, and their mutation 
frequencies clearly separated them from microsatellite stable (MSS) tumors (Fig. 2.3A). 
Yet MSS tumors also contained abundant mutations. These mutations were qualitatively 
different from those observed in MSI cancers, indicating slippage errors during normal 
DNA replication rather than defective DNA mismatch repair. Loss of DNA mismatch 
repair proteins, such as MLH1 and PMS2, leads to frequent generation of new alleles in 
the growing tumor and results in a distinctively broadened stutter distribution. The 
changes that we observed in MSS tumors, on the other hand, typically consisted of a 
shift of the stutter pattern by one or two base pairs without broadening of the 
distribution, pointing to the presence of just one new allele that was shared by a large 
percentage of sampled cells (Fig. 2.2B).  
We did not know a priori whether these new alleles were generated during tumor 
development or were already present in the tumor founder cell. In the latter case, the 
new variants would represent the mutational fingerprint a normal colonic stem cell 
acquired as it proliferated over a patient’s lifetime. Colonic stem cells divide very 
frequently – every 30 hours by some estimates (Potten et al., 1992) – and would 
therefore be expected to accumulate large numbers of mutations over the years, with  
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Figure 2.2: Poly-G mutations in 22 human colon cancers. (A) Mutation frequency 
plotted as mutations/number of interrogated loci for each patient. Clinical characteristics 
are listed in the table below, including microsatellite instability (red – unstable, green – 
stable), chemotherapy (red – neoadjuvant therapy, green – therapy naïve), extent of 
invasion (T4, red – through serosa; T3, orange – through muscularis propria into 
pericolorectal tissues; T2, yellow – through submucosa and extending into muscularis 
propria; T1, yellow  – into submucosa; Rec, blue – recurrence, no primary tumor), lymph 
node status (N2b, red – metastasis in 7 or more regional lymph nodes;  N2a, orange – 4 
to 6 lymph nodes; N1b, yellow – 2 to 3 lymph nodes; N1a, yellow – 1 lymph node; N1c, 
yellow – tumor deposits in the subserosa, mesentery or non-peritonealized pericolic or 
perirectal tissues without regional lymph node metastasis) and distant metastasis (red – 
present, green – absent) (B) PCR stutter distribution for marker Sal52 in a microsatellite 
stable cancer (top) and a cancer with microsatellite instability (bottom). The presence of 
a multitude of alleles in the MSI sample leads to a broadening of the distribution, 
whereas a simple shift indicates a single mutation in the microsatellite stable tumor.  
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Figure 2.3: Association of mutation frequency with age and grade. (A) Age is 
positively correlated with mutation load in microsatellite stable tumors, p=0.0416 (linear 
regression after exclusion of MSI cases, R2=0.23, Pearson correlation coefficient=0.48) 
(B) Low grade tumors contain more mutations than high grade tumors, p=0.0041 (two 
tailed Mann-Whitney test) 
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total mutational burden increasing with age. Recent studies show a correlation between 
age at diagnosis and total number of somatic mutations in acute myeloid leukemia 
(Welch et al., 2012) and colorectal cancer (Laiho et al., 2002; Tomasetti et al., 2013). 
We tested this correlation in our data set after excluding MSI cases, since a distinct 
mutational mechanism is operational in these tumors. We found significant positive 
correlation between patient age and mutation frequency (Fig. 2.3A), suggesting that the 
poly-G tract mutation profile partially reflects the genotype of the tumor founder cell. 
Tumor size, lymph node status and presence of distant metastases were not 
significantly associated with mutation frequency, but since we specifically selected 
cases with lymphatic or distant metastasis, our cohort is biased for patients with 
advanced disease and not suited for rigorously testing this relationship. Exposure to 
neoadjuvant chemotherapy was also not associated with the number of poly-G variants 
per tumor. However, we did find a highly significant inverse correlation between 
mutation frequency and tumor grade (Fig. 2.3B). Age and tumor grade did not correlate. 
Assuming the poly-G mutation profile is indeed shaped by the tumor founder cell’s 
genotype, this observation suggests that poorly differentiated tumors derive from a cell 
with relatively short mitotic history, such as a rarely dividing tissue stem cell. 
Polyguanine tract profiles generate a map of tumor evolution. 
To determine whether poly-G mutations could be used to reconstruct lineage 
relationships between multiple tumor samples from the same patient, we selected four 
patients whose primary tumors had mutations at more than 30% of investigated loci. For 
each patient, we then collected between 8 and 15 spatially separated samples from 
different regions of the tumor (primary tumor mass, lymph node metastases, distant 
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metastases). We generated poly-G tract profiles for each sample using the same 20 
markers used in our initial screen. To facilitate data analysis, we developed a semi-
automated method for converting poly-G stutter distributions into genotypes (detailed in 
Experimental Procedures and Supplementary Figure S8). Finally, we created 
phylogenetic trees illustrating the lineage relationships between all sampled tumor parts. 
Every patient’s tree provided unique insights into tumor evolution and metastatic 
progression as detailed below. 
Poly-G tract profiling assigns metastases to their tumor of origin. 
We began by examining a case in which the phylogenetic relationships were at least 
partially known. Patient C39 was a 66-year-old male who underwent total colectomy 
without neoadjuvant chemotherapy and was found to have two spatially separated foci 
of invasive carcinoma, a 5.5 cm tumor in the cecum that arose within an adenoma and a 
6 cm tumor in the sigmoid colon. Both cancers were low grade. One of the dissected 
lymph nodes near the inferior mesenteric artery revealed metastatic carcinoma in close 
proximity to the sigmoid tumor. We asked whether poly-G tract profiling could accurately 
identify lineage relationships in this patient by determining the two carcinomas’  
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Figure 2.4: Patient C39 with two synchronous adenocarcinomas of the colon. CT 
– Cecal tumor, ST – Sigmoid tumor, LN – Lymph node metastasis, LM – Liver 
metastasis, N – Normal. Tumor sizes are drawn to scale. Letters A and B indicate that 
two samples were taken from the same FFPE block. Additions “P” and “Sec” indicate 
that a block was analyzed twice, once via punch biopsy (P) and once via 
macrodissection of tissue sections (Sec). All other samples are derived from separate 
blocks. The phylogenetic tree was constructed by neighbor joining. Confidence values 
for each interior branch were calculated from 1000 bootstrap replicates. Branches with 
confidence values below 70% were collapsed into polytomies. 
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Figure 2.4 (Continued).  
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independent origins and linking the lymph node metastasis to its tumor of origin in the 
sigmoid colon. We found 7 variants in the most mutated parts of the cecal tumor, and 7 
in the sigmoid lesion. That the tumors had the same number of mutations suggested 
similar mitotic ages, yet the mutations were largely mutually exclusive. (Full genotype 
data and a heatmap of all mutations can be found in Supplementary Table S3 and 
Supplementary Figure 1, respectively. Since both tumors had similar numbers of 
mutations, only the sigmoid tumor is depicted in the overview in Figure 2.2) The 
phylogenetic tree constructed from these data located the two tumors in two 
independent evolutionary branches with high confidence values based on 1000 
bootstrap replicates (Figure 2.4). The lymph node metastasis was correctly assigned to 
the sigmoid tumor’s branch. One year after the initial surgery, and after six cycles of 
adjuvant chemotherapy with FOLFOX (folinic acid, fluorouracil, oxaliplatin), two liver 
metastases (1 cm and 0.5 cm) were resected. We genotyped the smaller lesion, and 
phylogenetic reconstruction connected it to the same evolutionary branch as the 
sigmoid tumor and excluded the cecal carcinoma as a source of metastasis. Notably, 
the liver lesion had the same mutational profile as sigmoid tumor area ST1, which was 
removed before administration of adjuvant chemotherapy. 
Extensively diversified primary tumor gives rise to homogeneous metastasis. 
Patient C13 was an 83-year-old female with a 7.0 cm invasive colonic adenocarcinoma 
and metastases to the left and right ovaries (Figure 2.5A). All lesions were removed in 
one surgery, and the patient did not receive any prior chemotherapy. The tumor was 
moderately differentiated (Figure 2.5B), microsatellite stable, and involved the ileum,  
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Figure 2.5: Patient C13 with invasive adenocarcinoma of the colon and metastasis 
to the ovaries. (A) Approximate anatomical localization of all analyzed samples. PT – 
Primary tumor, RO – Right ovary Metastasis, LO – Left ovary Metastasis, N – Normal. 
Tumor sizes are drawn to scale. Letters A and B indicate that two samples were taken 
from the same FFPE block. All other samples are derived from separate blocks. The 
surgical pathology report provides a description of each tumor block, but the exact 
spatial orientation of each sample is not always known. For example, PT3-A and PT3-B 
are located in the ileum, and PT1 and PT2-7 are located in the cecum, but consecutive 
numbers do not necessarily imply that the tumor samples are adjacent to each other. 
(B) Histological images of tumor regions PT4, PT5, PT6 and LO3. Scale bar 20 µm. (C) 
Neighbor-joining tree with bootstrap values, branches with bootstrap values below 70% 
collapsed into polytomies. (D) Complete mutation heatmap. Grey squares signify allele 
distributions that are indistinguishable from normal control. Colored squares indicate a 
shift in allele distribution, i.e. a poly-G mutation. If multiple different distributions exist 
per marker, they are indicated with additional colors. White squares indicate missing 
data due to amplification failure. 
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ileocecal valve, and cecum. We generated poly-G tract profiles for 3 normal tissue 
samples, 8 primary tumor samples, 3 right-ovary metastasis samples, and 4 left-ovary 
metastasis samples. (A detailed description of specimens based on the surgical 
pathology report and the full genotype data are provided in Supplementary Table S4.) 
14 loci were mutated in at least one sample, and each sample contained at least 7 
distinct mutations. (Figure 2.5C depicts patient C13’s phylogenetic tree, and a complete 
heatmap of all mutations is shown in Figure 2.5D.) As expected, all normal samples had 
the same genotype across all poly-G tracts. The primary tumor, by contrast, was highly 
diversified. Tumor regions PT5 and PT7 clustered in a distinct branch that had 
segregated from the rest of the tumor very early in its evolution. Neither region shared 
the majority of mutations found in other parts of the tumor, but instead harbored unique 
variants not found in any other sample. The ileal portion of the tumor (PT3-A and PT3-
B) produced 2 samples that were identical to each other, yet distinct from the cecal part 
of the tumor, and located on a separate branch of the tree. Tumor regions PT1 and PT6 
shared a majority of mutations and were almost identical to samples from the ovarian 
metastases. All metastases clustered together on the branch with the greatest “depth” 
(Wasserstrom et al., 2008b), i.e. the branch that contained the most mutated samples 
and was separated from the normal root by the greatest number of cell divisions. The 
tree allowed us to answer several important questions about this cancer’s evolution. We 
observed extensive spatial heterogeneity within the primary tumor, indicating that clonal 
populations had evolved locally for some time without intermixing. Some parts were so 
distinct from each other that we could not detect any shared mutations (e.g. PT5 vs. 
PT1). In contrast to the primary tumor, the metastases showed only minimal 
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diversification. This is consistent with a model of late metastasis, in which a genetically 
advanced clone (residing in PT1 or PT6) gives rise to all metastases in quick 
progression or in which one ovary metastasis gives rise to the other. 
Lymph node metastases can be phylogenetically distinct from distant metastases. 
Patient C13’s left and right ovary metastases were similar to each other, but we also 
found genetically divergent metastases. Patient C31 was a 48-year-old female who 
received neoadjuvant FOLFOX chemotherapy and underwent surgery for a 3.2 cm 
microsatellite stable adenocarcinoma located at the hepatic flexure and a large 13 cm 
metastasis to the right ovary (Figure 2.6).  
 
 
 
 
 
 
 
 
 
 
Figure 2.6 : Patient C31 with adenocarcinoma of the colon, lymph node and 
ovarian metastases. PT – Primary tumor, RO – Right ovary Metastasis, LN – Lymph 
node metastasis N – Normal. Tumor sizes are drawn to scale. Neighbor-joining tree with 
bootstrap values, branches with bootstrap values below 70% collapsed into polytomies. 
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The tumor had also metastasized to the mesenteric lymph nodes. We isolated four 
primary tumor samples, 8 right ovary metastasis samples, and two tumor samples from 
the mesenteric lymph nodes. In the primary tumor, mutations were present in 33% of 
interrogated poly-G tracts.  (The full genotype data can be found in Supplementary 
Table S5; the mutation heatmap in Supplementary Figure S4). As in patient C13, patient 
C31’s phylogenetic reconstruction showed that the ovarian tumor was distinct from the 
primary cancer and formed the deepest branch of the tree (Figure 2.6). The metastasis 
had an approximately 40-fold larger volume, implying that the metastatic clone must 
have been able to substantially increase its net growth rate (possibly this “growth spurt” 
happened in the early developmental stages of the metastasis, before it reached its 
substantial size). Given the relatively large number of mutations distinguishing the 
primary tumor and the ovarian metastasis, it is possible that they evolved separately for 
a substantial amount of time (consistent with parallel progression). However, we cannot 
exclude the possibility that we simply failed to sample the primary tumor region that 
contained the metastatic clone. Interestingly, the ovarian clone did not spread to the 
lymph nodes: two independent samples from a large mass of matted lymph nodes were 
almost identical to the primary tumor in genetic composition across all markers. This 
finding shows that a primary tumor can contain multiple populations of clones with 
metastatic ability and raises the intriguing question of whether different routes of 
metastasis (lymphatic, hematogenous, intraperitoneal) are favored by genetically 
divergent cells. 
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A primary tumor and its widespread metastases are genetically homogeneous. 
Poly-G tract profiling of patient C27, a 44-year-old male with a mucinous 
adenocarcinoma that had spread extensively throughout the abdominal cavity, revealed 
a fundamentally different tumor evolution pattern than patients C13 and C31. Patient 
C27’s descending colon harbored a small 1.5 cm tumor continuous with a 34.5 cm 
lesion that had essentially replaced the greater omentum. In addition to this large mass, 
several serosal nodules and a splenic metastasis were resected after a course of 
neoadjuvant chemotherapy with FOLFOX and radiation treatment. The tumor was 
microsatellite unstable, and the mutation rate was high with somatic alterations 
observed in 45% of interrogated loci. (Full genotype data provided in Supplementary 
Table S6; mutation heatmap in Supplementary Figure S6.) In contrast to patients C13 
and C31, whose samples revealed substantial variation, all specimens from patient C27 
had essentially the same poly-G tract profile, and the topology of the resulting 
phylogenetic tree was flat (Figure 2.7). Evidently, the tumor grew from a small lesion in 
the colon into a large omental mass and seeded a number of metastases while 
undergoing no significant spatial diversification. This is particularly surprising because 
this tumor was larger than the tumors in either patient C13 or C31, and its mutation rate 
was elevated due to MSI. Both these factors would be expected to lead to increased 
levels of diversity across different regions of the neoplasm (Marusyk et al., 2012). It 
therefore appears that one rapid clonal expansion that did not allow for regional 
“speciation” events created this cancer. Alternatively, patient C27’s tumor cells may 
have had an exceptionally high motility, resulting in extensive mixing that rendered new 
clones generated during tumor growth undetectable. Both explanations, which are not 
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mutually exclusive, point to an exceptionally aggressive phenotype. Future studies will 
determine whether spatial homogeneity is an adverse prognostic factor in colon cancer. 
 
 
 
 
 
Figure 2.7: Patient C27 with mucinous adenocarcinoma of the colon. SP – Spleen 
metastasis, SN – Serosal nodule, OM – Omentum, MM – Mesenteric margin, RM – 
Retroperitoneal margin, PS – Peritoneal side wall metastasis, N - Normal. Neighbor-
joining tree with bootstrap values, branches with bootstrap values below 70% collapsed 
into polytomies.   
 68 
Polyguanine mutations are present in a variety of other human cancers. 
By testing a small panel of human tumors at 12 or more poly-G loci, we found 
polyguanine mutations in several cancer types in addition to colon cancer, including 
renal cell carcinoma, glioblastoma, cholangiocarcinoma, esophageal carcinoma, 
pancreatic islet cell tumor, breast cancer, and lung carcinoid tumor (Supplementary 
Tables S7-S10). Our dataset is not comprehensive enough to determine average tumor 
mutation frequency in cancers other than colon, though ongoing investigation of a 
breast carcinoma cohort indicates that variants are less frequent in this cancer type, 
presumably because breast epithelial cells do not divide as frequently as colonic cells.  
Initial results suggest that the observed distinction between spatially 
heterogeneous and homogeneous tumors in colon cancer will also apply to other 
cancers. For example, one renal cell carcinoma showed a 33% mutation frequency, but 
most mutations were only detectable in select tumor portions (Supplementary Table 
S9). Analysis of a breast cancer (patient B1, Figure 2.8A) comprising two lymph node 
metastases and four tumor nodules separated by several centimeters indicated that all 
lesions had a common origin because they shared some variants. However, we also 
found heterogeneously distributed mutations that allowed us to deduce that tumor focus 
TF1 had seeded the larger lymph node metastasis LN2, while tumor focus TF4 
contained a distinct mutational profile and had segregated early on in its evolution. By 
contrast, patient O1’s (Figure 2.8B) malignant peripheral nerve sheath tumor showed 
homogeneity similar to patient C27’s colon cancer. Patient O1 had a 14 cm calf tumor 
and a histologically similar 1.7 cm cancer on his left hand resected, and one year later 
he underwent excision of a 6.5 cm lung metastasis. Poly-G tract profiling revealed  
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Figure 2.8: Patient B1 with multifocal breast cancer and patient O1 with malignant 
peripheral nerve sheath tumor.  (A) Patient B1. TF – Tumor focus, LN – Lymph node 
metastasis, N – Normal. Neighbor-joining tree with bootstrap values, branches with 
bootstrap values below 70% collapsed into polytomies. (B) Patient O1. LCT – Left calf 
tumor, LH – Left hand nodule, LuM – Lung Metastasis, N- Normal. Additions “Sec” and 
“P” indicate that the sample was analyzed twice, once using a biopsy punch (P), and 
then by retrieving tumor tissue from sections (Sec). Neighbor-joining tree with bootstrap 
values, branches with bootstrap values below 70% collapsed into polytomies. 
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identical mutations in all 8 calf tumor and two lung metastasis samples, which suggests 
that the calf tumor was the source of the lung metastasis, while the tumor in his left 
hand showed no alterations and likely represented an independent transformation.  
2.5 Discussion 
We have shown that somatic mutations in non-coding poly-G repeats can be used to 
build maps of clonal architecture in human cancers. Poly-G tract profiling is sensitive 
enough to detect many distinct clonal populations within a tumor and produces reliable 
phylogenies that elucidate each patient’s individual path of progression. The technique 
is widely useful in outlining clonal expansions that occur during carcinogenesis. 
In two patients with clear genetic divergence between primary and distant 
lesions, the metastases shared some alterations with the primary tumor but had also 
acquired private mutations. These data are consistent with previous findings in 
colorectal cancer (Jones et al., 2008) and pancreatic cancer (Yachida et al., 2010). 
Patient C13’s cancer supports the late metastasis paradigm. Patient C31 could 
potentially represent a case of parallel progression because relatively few mutations are 
shared between the distant metastasis and the primary tumor, but with the caveat that 
sampling of the primary tumor might have missed the metastatic clone. In two other 
patients (C39 and C27), primary tumors and metastases shared a majority of mutations 
and were phylogenetically indistinguishable at the given resolution.   
In two instances, we had the opportunity to compare distant and lymphatic 
metastases. In one patient (C31), we found that cancer cells that had disseminated to 
the lymph nodes had the same genotype as the primary tumor, while a distant ovarian 
metastasis had a distinct mutational profile and contained many private alterations. Two 
 72 
plausible explanations exist for this result. It is possible that after the ovarian metastasis 
had already formed, a sweeping clonal expansion occurred in the primary tumor and 
gave rise to the lymph node metastasis. However, this hypothesis does not account for 
the larger mutational load in the ovarian metastasis, which suggests that its founder 
clone had undergone a larger number of divisions than the clone dominating the primary 
tumor and the lymph node metastasis. An alternate explanation more consistent with 
our data is that large numbers of tumor cells continuously drain from the original site to 
the lymph node, which contains a polyclonal sample of cells from the primary tumor and 
is therefore indistinguishable from it. Future studies will determine, in a larger cohort of 
patients, whether genetic divergence between lymph node and distant metastases is a 
more general phenomenon. It would be of significant clinical and biological interest to 
evaluate whether lymphatic metastases might be formed through a distinctive migration 
mechanism. 
Clonal diversity varies substantially between patients. Some tumors were 
diversified (C13, C31, B1), while others shared the same genotype across all primary 
and metastatic tumor samples (O1), in one case despite an elevated mutation rate 
caused by microsatellite instability (C27). We did not find any obvious connection 
between administration of chemotherapy prior to surgery and intra-tumor heterogeneity. 
For example, both patients C31 (diversified) and C27 (homogeneous) received 
neoadjuvant chemotherapy with FOLFOX. While the “flat” clonal expansions (Siegmund 
et al., 2009) clearly represent younger entities than the diversified cancers (Shibata et 
al., 1996), we currently do not know whether these differences in population structure 
are mirrored in divergent clinical behavior. Clonal diversity in the premalignant lesion of 
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Barrett’s esophagus represents a risk factor for future cancer development (Maley et al., 
2006), which suggests that heterogeneity promotes malignancy, but the situation may 
be different in established cancers and/or differ by cancer type. In breast cancer, intra-
tumor heterogeneity, as defined by cell surface marker expression, correlates with 
histopathological stage (Park et al., 2010), but how phenotypic heterogeneity relates to 
genetic diversity is not known. Determining whether genetic heterogeneity, or lack 
thereof, is associated with important clinical variables will be important in future studies. 
One limitation of our approach in this regard is that it relies on spatially distinct clonal 
expansions. Genetic heterogeneity within a sample cannot be detected if an allele is 
present at a frequency below 40-60% (Salk et al., 2009). Subclonal diversity below this 
threshold should therefore be evaluated with complementary techniques such as 
fluorescence in situ hybridization (Snuderl et al., 2011) or deep sequencing (Ding et al., 
2010). 
Our data further show a positive correlation between age at diagnosis and 
mutation frequency. This result accords with growing evidence that a large proportion of 
mutations (more than 50% by some estimates (Tomasetti et al., 2013)) found in human 
cancers are not acquired during tumor development but are already present in the 
tumor founder cell. Mutations accumulate in normal cells but typically remain 
undetectable because no clonal expansion takes place. Recent work shows that after 
expansion of single normal human hematopoietic stem cells, comparable numbers of 
mutations can be observed as in acute myeloid leukemia (Welch et al., 2012). Since 
cells in different human tissues proliferate at varying rates, the mitotic history of a tumor 
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founder cell is likely a significant factor in the variation among cancer mutation rates 
(Lawrence et al., 2013). 
Intriguing in this context is that mutation frequency inversely correlates with 
tumor grade. Poorly differentiated tumors have significantly fewer poly-G mutations. 
Extending the argument that mutation frequency is determined by the mitotic history of 
the tumor founder cell, this observation suggests that less differentiated tumors derive 
from a rarely dividing cell. In the colon, two distinct progenitor populations have been 
identified, one displaying the characteristics of an actively dividing tissue stem cell that 
continuously replenishes the epithelial compartment, the other showing signs of 
quiescence (Li and Clevers, 2010). It may be that poorly differentiated tumors arise from 
the latter population. Future studies will also determine if somatic mutation load can 
predict colon cancer patient survival. 
In summary, we have shown that a highly scalable PCR assay of endogenous 
mutational hotspots can generate reliable lineage information in human cancer with low 
time and cost expenditures. We have used this assay to generate unique biological 
insights into the origin and progression of metastatic colon cancer. Our methodology 
can be used with FFPE specimens, which are collected in hospitals around the world on 
a daily basis. Our study only used tissues that were also available to the pathologist at 
the time of diagnosis. It is conceivable that lineage testing could be quickly performed 
for individual patients in order to improve clinical decision processes. Since detecting 
mutated alleles in poly-G tracts does not require sequencing, patient privacy would be 
protected. In addition to its diagnostic potential, poly-G tract profiling can be used in its 
own right to study tumor evolution or to efficiently screen samples for deeper analysis 
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by next-generation sequencing. Successfully developing and applying targeted cancer 
therapies will depend on accurately understanding clonal architecture in human tumors. 
A neoplasm’s mitotic history, as captured by neutral lineage markers, will provide an 
important backdrop on which to project the distribution of numerous therapeutically 
relevant mutations.  
2.6 Experimental Procedures 
Patient selection and tissue collection 
This study was approved by the IRB of Massachusetts General Hospital, Boston, MA. 
We searched the pathology database of Massachusetts General Hospital for patients 
who underwent surgery between 2010 and 2012 and whose diagnosis contained ICD9 
code 153, “Malignant neoplasm of the colon.” We reviewed the search results and 
selected 22 consecutive patients who underwent resection of a primary colon carcinoma 
along with at least three lymph node metastases and/or distant metastases. 18 patients 
were treatment naïve, three had received neoadjuvant chemotherapy, and one patient 
received neoadjuvant chemotherapy and radiation. Detailed patient information is 
provided in Supplementary Table 1. For each patient, we reviewed all available 
histology slides and FFPE tissue blocks and selected areas of homogeneous tumor for 
sampling. Tumors with predominant stromal component were excluded. By default, we 
used a 1.5 or 2 mm biopsy punch to extract cores of tumor and normal tissue directly 
from the block. For small tumor samples, we cut 10 µm tissue sections and 
macrodissected tumor cells after staining slides with a PCR-compatible stain 
(Histogene, Life Technologies). Samples were de-paraffinized with xylene, washed with 
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100% ethanol, air-dried, and incubated with Proteinase K overnight as previously 
described (Shibata, 1994). DNA was extracted with phenol-chloroform and precipitated 
with ethanol. We estimate that the average tissue sample had a volume of 3 mm3 and 
contained 9x106 cells.  
Genotyping 
A panel of primers flanking 35 poly-G tracts in the human genome was previously 
published (Salk et al., 2009). We used a randomly selected subset of primers from this 
panel (20 loci were sufficient to generate reliable phylogenies in our patients).  Marker 
identification numbers are provided alongside full genotype data in all Supplementary 
Tables. Forward primers incorporated a fluorescent dye (HEX or 6-FAM) on their 5’ end. 
Reverse primers contained a 5’ GTTTCTT “pigtail” sequence (Brownstein et al., 1996). 
Since our DNA was derived from FFPE tissue and heavily fragmented, we included 90 
ng of DNA (as determined by spectrophotometry) in each reaction to ensure the 
reproducibility of stutter patterns. Every PCR was performed in triplicate in a 10 µL 
volume with 1µM forward and reverse primers, 200µM of each dNTP, 2.5 units Taq 
Polymerase, 1x PCR buffer, and 1x Q-solution (Qiagen) to facilitate amplification of GC-
rich templates. After 42 amplification cycles, PCR products were resolved by capillary 
electrophoresis using an ABI Genetic Analyzer 3130xl. Microsatellite instability was 
tested using the Bethesda Markers as described in (Loukola et al., 2001). We did not 
distinguish between MSI-low and microsatellite stable tumors. Electropherograms were 
viewed with GeneMapper 4.0. The 22 tumor-normal pairs in our cohort were scored for 
the presence of mutations by visual comparison of the stutter distributions for each 
marker. If the tumor sample showed a consistent shift in the stutter pattern that was 
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reproducible across all three replicates, we recorded a mutant genotype, denoting a 
repeat contraction with m[number of deleted bases] and an expansion with p[number of 
added bases]. If two distinct alleles were discernible and at least 6 base pairs apart, we 
scored them separately. Instances of loss of heterozygosity were not counted as 
mutations, but they were used as data points in the phylogenetic reconstruction 
(described below). To facilitate analysis of multiple tumor regions from the same patient, 
we developed an automated approach that allowed us to compare stutter patterns 
across many samples in an objective manner. Supplementary Figure 5 provides an 
overview of our algorithm. We exported peak information (size, height) from 
GeneMapper and fed it into an analysis pipeline within the R environment for statistical 
computing (http://www.R-project.org). For each patient and marker, we calculated 
pairwise correlation coefficients among all stutter distributions and used these as input 
to a hierarchical clustering algorithm. The resulting dendrogram divided all samples into 
categories that corresponded to different mutations. We examined the branches of the 
dendrograms and determined at which height to cut the tree based on three criteria: 1) 
Normal samples had to cluster separately from mutated tumor samples, 2) replicates 
had to cluster within the same clade (allowing for some variation due to PCR failure), 
and 3) all mutation categories could be verified by manual review of electropherograms. 
Genotype assignments were recorded in a matrix that contained the mutational status of 
every sample at 20 poly-G loci. Since we did not want to make assumptions about the 
likelihood of a particular allele distribution occurring, we treated mutations as unordered 
characters. This data set was used for phylogenetic analysis. 
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Phylogenetic reconstruction 
We reconstructed phylogenies using two independent approaches. First, we calculated 
a distance matrix for each patient using an ‘equal or not’ distance (Frumkin et al., 2005) 
and employed neighbor-joining (Saitou and Nei, 1987) in R to infer the phylogenetic 
relationships between samples. We used bootstrapping with 1000 replicates to test the 
reliability of the resulting trees (Felsenstein, 1985) and collapsed all interior branches 
with bootstrap values below 70% into polytomies. Next, we used Bayesian inference of 
phylogeny – a methodology that relies on a fundamentally different set of principles than 
neighbor-joining – to construct the phylogenies. The results were almost identical in all 
cases, confirming the robustness of our approach. Bayesian phylogenies and posterior 
probability values for all clades are presented in Supplementary Figures 1-4. We used 
the software MrBayes (Huelsenbeck and Ronquist, 2001) with the same model 
parameters that were previously used for the analysis of poly-G tract mutation profiles 
(Salipante and Horwitz, 2006).  
Other statistical analyses 
Statistical analysis was performed in Prism (Graphpad). We used linear regression to 
test the association between mutation frequency in MSS tumors and four variables of 
interest (tumor size, lymph node status, presence of distant metastasis at diagnosis, 
age). We used a two-tailed Mann-Whitney test to compare mutation frequencies in low 
and high grade tumors (n=9 for each group after excluding MSI cases). We did not 
correct for multiple testing, as the number of tests was small and our sample size (n=18) 
limited (with correction, the p-value for the association between mutation frequency and 
grade would still be significant but the association with age would not). 
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Chapter 3: Discussion and future directions 
 
 
3.1 Summary 
The first chapter of this dissertation lays out a number of important questions regarding 
metastatic progression in humans. The development of effective treatment strategies for 
both localized and advanced disease requires precise knowledge of when metastatic 
precursors disseminate, by which routes they travel, and what their genetic relationship 
to the primary tumor is. It is likely that different cancer types metastasize along 
divergent paths and timelines. Reconstructing the “tree of life of metastatic cancer” in 
representative patient populations will help us formulate more precise disease models, 
which will in turn guide the design of improved treatment schemes. 
In the second chapter, I show how a simple PCR assay can be used to 
determine the lineage relationships between primary tumors and metastases in human 
colorectal cancer. The proposed methodology relies on small insertions and deletions in 
hypermutable polyguanine (poly-G) tracts that are introduced into the genome at high 
frequency in a replication-dependent manner. Poly-G variants that are distinct from the 
germline are present in 91% of colorectal cancers. A positive correlation of the tumor 
mutational load with age at diagnosis indicates that at least a portion of them are 
acquired during proliferation of normal colonic stem cells during the patient’s lifetime. 
Poorly differentiated tumors have fewer mutations than well-differentiated tumors, 
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possibly pointing to a shorter mitotic history of the tumor founder cell in high grade 
cancers.  
More poly-G mutations are acquired during clonal evolution. These variants can 
be used for lineage tracing. In four patients, I use poly-G fingerprints of various parts of 
the primary tumor and its metastases to construct phylogenetic trees that reflect 
evolutionary relationships among tumor cell populations. The phylogenies show that 
metastasis occurs relatively late in colon cancer progression. The level of regional 
genetic heterogeneity varies substantially among patients, implying that some tumors 
are created by rapid clonal expansions, while others undergo spatially discrete 
speciation events. Finally, I demonstrate the presence of poly-G variants in a number of 
other human cancer types. Poly-G tract profiling therefore has applicability beyond 
colorectal cancer.  
3.2 Methodological perspective 
Analysis of poly-G tracts for phylogenetic reconstruction of human cancer histories has 
several advantages over existing methods. First, the technique is highly scalable, 
making it suitable for analysis of large patient cohorts. Dozens of samples can be 
processed in parallel at low cost, using relatively common equipment: a PCR machine 
and a capillary sequencer. The sample preparation procedure – tissue digestion 
followed by DNA extraction with phenol-chloroform and precipitation – can be done in 
bulk. Pooling of PCR products labeled with three or more different fluorophores enables 
work-efficient fragment analysis by capillary electrophoresis. Multiplexing primers during 
amplification can further optimize the workflow, but this possibility has not been 
implement in our studies so far, partly because extensive reaction optimization is 
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required. Establishing a reliable multiplex protocol is one of our future goals. 
Another advantage is that DNA from formalin fixed paraffin embedded (FFPE) 
tissues is suitable for poly-G profiling. FFPE-derived DNA is fragmented and contains 
an abundance of artifactual single-nucleotide changes (Do et al., 2013). Obtaining good 
quality sequence data from FFPE tissue requires specialized approaches (Wagle et al., 
2012). Since the insertions and deletions that are characteristic of replication slippage in 
microsatellites are not typical artifacts of fixation, poly-G tract profiling is a reliable 
methodology for the analysis of FFPE-derived DNA. The problem of nucleic acid 
fragmentation, on the other hand, remains. Generation of reproducible poly-G tract 
genotypes therefore requires high template concentration (~ 90 ng) in each reaction. 
Finally, poly-G tract analysis does not produce any identifiable information that 
could be used to breach patient privacy. Most institutional guidelines prohibit whole 
genome or even exome sequencing of archival tissues without explicit consent. Hence, 
the large numbers of valuable cancer samples stored in pathology departments cannot 
be used for this purpose because patients would have to be contacted retrospectively, 
which is time-consuming for the investigator and potentially psychologically demanding 
for the patient. Poly-G tract profiling can be performed under most discarded tissue 
protocols, thereby opening up tissue resources for analysis of intra-tumor heterogeneity 
that would remain untapped otherwise. 
However, poly-G tract profiling also suffers from a number of significant 
limitations. First and foremost, fragment analysis is an analog technology with very low 
resolution. Alleles that are present at a frequency below 40% in a sample cannot be 
detected (Salk et al., 2009). Biologically relevant variation within a sample (local 
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intermingling of different clones) remains invisible below this threshold, but we know 
that many subclonal mutations are common in tumors and may play an important role in 
therapy resistance and relapse (Ding et al., 2010; Landau et al., 2013; Nik-Zainal et al., 
2012). Genetic analyses of di- and trinucleotide microsatellites have circumnavigated 
this limitation by performing digital PCR on extensively diluted samples, essentially 
amplifying single alleles (Tsao et al., 1998). For poly-G tract profiling, we have not been 
able to establish a similar approach to date. The mutation rates in poly-G tracts are 
exceedingly high, and the noise introduced during PCR appears to preclude reliable 
amplification of single molecules. 
An additional problem of fragment analysis is that in some cases mutations 
cannot be distinguished from loss of heterozygosity (LOH) (illustrated in Figure 3.1). 
Poly-G tract mutations most often occur in the form of 1 base pair (bp) insertions or 
deletions. If a clearly heterozygous allele (e.g. displaying two peaks at 120 and 130 bp) 
in normal tissue is reduced to a single peak at 120 bp in a tumor, it is reasonable to 
assume LOH. However, if an allele is heterozygous with two peaks at 120 and 121 base 
pairs, the probability of a mutation vs. LOH is unknown. For the purposes of all analyses 
in this dissertation, a change was scored as a poly-G tract mutation unless it 
represented an unambiguous case of LOH. Fortunately many heterozygous alleles are 
easily distinguishable from each other, so it is unlikely that this limitation generated 
significant biases in the data. 
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Figure 3.1: Ambiguity between one base pair deletion and LOH. (A) Normal tissue 
control and (B) tumor genotype for marker Sal104. The distribution shift could be 
caused a one base pair contraction of the poly-G tract, or represent loss of the upper 
allele. 
130/131
130
A 
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Finally, while poly-G tracts, due to their neutrality and high mutability, are of great 
interest for somatic lineage tracing, they do not lend themselves to parallelized 
measurement by current sequencing technologies. Ideally, all ~4000 intergenic poly-G 
tracts (see Table 1.3) would be captured and sequenced simultaneously in a sample of 
interest to yield a high-resolution fingerprint of somatic lineage. However, the typical 
PCR stutter that accompanies amplification of homopolymers prevents the generation of 
truly clonal clusters that are the basis of high quality sequence reads. It would be worth 
exploring whether parallelized interrogation of less mutable microsatellites (e.g. 
dinucleotide repeats) could be used for this purpose instead. Alternatively, development 
of single molecule sequencing technologies that can reliably interrogate homopolymers 
(perhaps Nanopore sequencing (Hayden, 2012)) might enable genome-wide evaluation 
of somatic poly-G variants in the future. 
 
3.3 Biological perspective: insights and ongoing follow-up studies 
In our study of poly-G mutation patterns in colorectal cancer, we made multiple 
intriguing observations that serve as sources of novel hypotheses.  
A large majority (91%) of patients in our cohort had at least one poly-G mutation, 
but the percentage of mutant genotypes (excluding cases with microsatellite instability) 
varied from 4.76% to 55%. To define the factors driving this large variation is one of our 
ongoing efforts. The total mutational burden of a sample consists of two components 
(summarized in Figure 3.2): mutations that were already present in the tumor founder 
cell at the time of transformation (fully clonal “founder mutations”, inherited by all cells) 
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Figure 3.2: Founder and progressor mutations. Mutations found in a tumor can be 
subdivided into those that were acquired during embryogenesis and normal tissue 
homeostasis (founder mutations) and those that accumulated during tumor evolution 
(progressor mutations). Under the simplifying assumption of similar mutation rates 
across tumors, the total number of variants is a function of the mitotic age of the founder 
cell (top panel) and the number of divisions that occurred before the tumor reached a 
given mass (bottom panel). Cells with different genetic alterations are indicated in 
different colors. The larger the number of divisions that occurred during tumor 
progression, the larger the potential for genetic heterogeneity is. 
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and mutations that emerged during tumor evolution (“progressor mutations” (Yachida et 
al., 2010): these can be subclonal, or clonal if completely sweeping expansions took 
place during tumor development (Greaves and Maley, 2012)). The number of divisions 
the tumor founder cell underwent before it became neoplastic mainly determines the 
former category. As discussed in chapter 2, a large portion of alterations in a tumor are 
probably founder mutations (Tomasetti et al., 2013; Welch et al., 2012). Age and 
patient-specific epithelial proliferation characteristics – inflammation and the associated 
cell turnover, for example – likely play a role in determining how large the contribution of 
founder mutations to the total burden is. Subclonal progressor mutations are relevant for 
lineage tracing purposes, and their number is intimately associated with the growth 
dynamics of a tumor. If a cancer grows aggressively, i.e. proliferation levels far exceed 
apoptosis levels, relatively few cell divisions are required to generate a mass of a 
certain size and intra-tumor diversification will be limited (Figure 3.2, lower right panel). 
If proliferation and apoptosis are more balanced, on the other hand, more cell divisions 
will be required for the development of a detectable tumor, and more pronounced 
regional speciation might take place (Figure 3.2, lower left panel).  
At least two exceptions to this logic are worth noting here. First, “regional 
speciation”, which has been documented in multiple cancer types (Gerlinger et al., 
2012; Yachida et al., 2010), is contingent on limited mobility of emergent clones. (This 
possibility is not depicted in Figure 3.2.) If cells within the tumor travel and intermingle 
extensively, new mutations will be diluted and thereby obfuscated. A lack of detectable 
progressor mutations can therefore be caused by rapid clonal expansion or increased 
cell mobility. Second, fully clonal progressor mutations cannot be distinguished from 
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founder mutations. 
Founder and progressor mutations are products of two fundamentally different 
biological processes: normal cell renewal during tissue homeostasis vs. tumor growth. 
Despite the caveats noted above, it will be of high interest to separate these two 
mutation types as cleanly as possible, determine whether their proportions differ among 
tumors and assess whether their relative characteristics are correlated with clinical 
variables. 
We are currently exploring the provenance of both founder and progressor 
mutations in more detail. In collaboration with the Department of Pathology at 
Massachusetts General Hospital, we have begun analyzing a cohort of 75 colon 
carcinomas that were resected at stage T3N0M0 (tumor invades through muscularis 
propria into pericolorectal tissues, no lymph node or distant metastasis). Detailed 
survival information is available for all patients. For our analysis, we are relying on the 
following simplified assumption: founder mutations are those that are present in all 
tumor regions, progressor mutations are only found in some locations. We plan to 
sample each tumor in multiple distinct places, generate poly-G tract genotypes, and 
calculate two distinct measures: 1) the “founder mutation score” which corresponds to 
the number of alterations that are found in all samples and therefore are clonal at our 
level of resolution and 2) a “heterogeneity score” corresponding to subclonal mutations 
that reflects the degree of regional diversification that has taken place. 
The working hypotheses related to these measures of interest are: 1) Low 
founder mutation frequency characterizes aggressive cancers and is correlated with 
shorter survival. 2) Homogeneous tumors with low heterogeneity scores are more lethal 
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than heterogeneous tumors and associated with shorter survival. They arise from the 
rapid expansion an inherently aggressive clone and do not have time to diversify. 
Both these hypotheses are driven by our observation that a low overall mutation 
frequency (consisting of founder mutations + progressor mutations) is correlated with 
high histological grade and therefore indicative of a more malignant phenotype (Figure 
2.3B). However, in our single sample analysis we could not distinguish between founder 
and progressor mutations. Consequently, it is possible that the inverse correlation of 
grade and mutation frequency is caused either by founder or by progressor mutations or 
by both. Given the unambiguous association of overall mutations frequency with patient 
age, we favor founder mutations as the driving factor (and this interpretation is mainly 
embraced in chapter 2), but a more thorough analysis of multiple tumor regions in the 
manner proposed above will shed more definitive light on this question.  
One caveat is that our approach is likely to overestimate the contribution of 
founder mutations. Some mutations will be categorized as clonal even though finer 
sampling might reveal that they are not present everywhere. Also, our technique cannot 
precisely estimate mutant allele frequencies; some mutations will be classified as clonal 
even though they are not present in all cancer cells, but only in a large fraction. Ideally, 
the experiment would be accompanied by deep sequencing of individual samples to 
capture intra-sample heterogeneity and quantify mutant allele frequencies more 
precisely, but this is likely impossible due to the patient privacy protections described 
above. 
Independently, to further characterize founder mutations in the colon, we would 
like to assess how many poly-G variants are normally present in colonic stem cells in 
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subjects of varying ages. Understanding the “baseline mutational load” of normal cells 
will give us a more precise idea of the average percentage contribution of founder 
mutations to the total mutational burden of a colon cancer. To this end, we are 
collaborating with a group in the Netherlands that specializes in culturing organoids 
derived from single human colonic crypts (Jung et al., 2011). These organoids are close 
progeny of a single colonic stem cell. We will genotype organoids from young children 
and elderly subjects and determine i) how their mutational burden compares to the 
number of alterations observed in colon cancer and ii) whether the positive correlation 
between mutational load and age is reproduced in normal tissues. 
3.4 Future directions 
A plethora of clinically relevant questions related to the work described here await 
resolution. Many could be addressed effectively with a combination of poly-G tract 
profiling and deep sequencing. 
For example, a systematic analysis of how the degree of intra-tumor 
heterogeneity changes at different progression stages would be very instructive. Very 
few studies have been conducted in this area. High levels of heterogeneity are 
connected with increased malignant potential in the early stages of tumorigenesis. For 
example, clonal diversity in Barrett’s esophagus, a premalignant condition, is linked with 
a higher likelihood of progression to cancer (Maley et al., 2006). The final step of 
systemic disease advancement, metastasis, on the other hand, appears to go hand in 
hand with a steep drop in heterogeneity. This makes intuitive sense, as dissemination 
represents a natural evolutionary bottleneck, and it is evident on multiple levels of 
observation: in the narrowing of the mutant allele frequency distribution in metastasis, 
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observed in breast carcinoma (Ding et al., 2012), apparent monoclonality of multiple 
lesions at the time of death in prostate cancer patients (even though localized prostate 
cancer often is multifocal and highly heterogeneous) (Liu et al., 2009), increased 
homogeneity of genomic rearrangements in DTCs derived from patients with overt 
metastasis vs. those with MRD (Klein et al., 2002; Weckermann et al., 2009), and our 
results presented in Chapter 2, in particular, the homogeneity of metastases in 
comparison with the primary tumor in patient C13. Parallel comparisons of cancer at 
different stages of advancement, conducted with standardized techniques, will further 
elucidate whether dynamic changes in diversity accompany progression. 
Also, it is unclear how the drop in heterogeneity suspected to occur in metastatic 
disease relates to treatment response. Darryl Shibata, a pioneering scientist in the field 
of intra-tumor heterogeneity, wrote in a recent perspective: “Targeted therapies should 
be directed at public driver mutations present in all cancer cells, but the probability of 
drug-resistant variants increases with cell division. Therefore, a more heterogeneous 
tumor with many private mutations is more likely to fail chemotherapy” (Shibata, 2012). 
Metastases (at least those arise synchronously or almost synchronously) are younger 
clonal expansions than primary tumors, as such they should be more responsive to 
therapy. This appears to be true for some cancer types. Clinical studies have shown 
that primary lung carcinomas, for example, are much less likely to respond to 
chemotherapy than corresponding metastases (11.8% vs. 32.8% response rate). For 
breast cancer, however, this pattern is reversed (40% vs. 19.8% response rate for 
primary tumors vs. metastases) (Slack and Bross, 1975). It is known that 
microenvironmental cues at different sites contribute to differential therapy response 
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(Kodack et al., 2012), but more rigorous investigation of how intra-tumor heterogeneity 
relates to these treatment outcomes will also be important in the future. 
Another interesting and unanswered question is how spatial diversification – the 
presence of distinct clones in different regions of a tumor – relates to strictly local 
heterogeneity (intermingling of clones), and how these forms of diversity associate with 
clinical behavior. More invasive and motile cells might generate more “dispersed” forms 
of genetic heterogeneity. It has furthermore been suggested that locally co-existing 
clones might be able to develop commensal relationships (Merlo et al., 2006) and 
cooperate to achieve greater fitness. One speculation could therefore be that high levels 
of local heterogeneity are a hallmark of aggressive disease, while regional clonal 
expansions that stay delineated from each other might signify more indolent 
phenotypes. Currently, no data exist to corroborate or refute this hypothesis. 
The answers to these and many other crucial questions in the field of intra-tumor 
heterogeneity are now within our reach. This is in large part due to the development of 
revolutionary next generation sequencing technologies and other important technical 
advances. Poly-G tract profiling is a small, but potentially useful addition to the growing 
repertoire of techniques that can collectively help us shine a bright light on the cells that 
are responsible for the deaths of far too many cancer patients. 
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Figure S1: Mutation heatmap patient C39.  Grey squares signify allele distributions 
that are indistinguishable from normal control. Colored squares indicate a shift in allele 
distribution, i.e. a poly-G mutation. If multiple different allele distributions exist per 
marker, they are indicated with additional colors. 
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Figure S2: Bayesian phylogeny patient C39. Posterior probability values for each 
clade are given as branch labels. 
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Figure S3: Bayesian phylogeny patient C13. Posterior probability values for each 
clade are given as branch labels. 
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Figure S4: Mutation heatmap patient C31.  Grey squares signify allele distributions 
that are indistinguishable from normal control. Colored squares indicate a shift in allele 
distribution, i.e. a poly-G mutation. If multiple different allele distributions exist per 
marker, they are indicated with additional colors. 
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Figure S5: Bayesian phylogeny patient C31. Posterior probability values for each 
clade are given as branch labels. 
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Figure S6: Mutation heatmap patient C27.  Grey squares signify allele distributions 
that are indistinguishable from normal control. Colored squares indicate a shift in allele 
distribution, i.e. a poly-G mutation. If multiple different allele distributions exist per 
marker, they are indicated with additional colors. 
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Figure S7: Bayesian phylogeny patient C27. Posterior probability values for each 
clade are given as branch labels. 
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Figure S8: Analysis algorithm flowchart. Detailed description in Chapter 2, 
Experimental Procedures 
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Table S1: Clinical characteristics of 22 colon cancer patients. FOLFOX - 
Chemotherapy regimen of folinic acid, fluorouracil, oxaliplatin. FOLFIRI - Chemotherapy 
regimen of folinic acid, fluorouracil,irinotecan. IHC -Immunohistochemistry. Bat25, 
D17S250, Bat26, D5S346, D2S123 - Bethesda Panel microsatellite markers. 
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Table S2: Genotyping information for all patients (separated into four parts). Four 
cases that were analyzed in more detail are excluded and instead presented in tables 
S3-S6. The 20 interrogated poly-G loci are listed in the rows of the table (Sal104-Sal21). 
For each patient, the length of the PCR product in tumor and normal control tissue is 
shown. Deletions are recorded as m[number of deleted bases] and marked in red, 
insertions as p[number of inserted bases] and marked in orange. If a locus was clearly 
heterozygous in a patient (6 or more base pairs length difference), we marked the locus 
in blue, scored the two alleles independently and increased the “total # of loci scored” 
count by one if both alleles could be evaluated in both tumor and normal (i.e. if one 
allele was not lost in the tumor, such as Sal30 in C18). Unambiguous loss of 
heterozygosity is highlighted with a blue background and not counted as a poly-G 
mutation. 
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Table S3: Genotyping information for all samples collected from patient C39. Poly-
G loci are listed in the rows of the table (Sal104-Sal21). Deletions are recorded as 
m[number of deleted bases] and marked in red, insertions as p[number of inserted 
bases] and marked in orange. If a locus was clearly heterozygous (6 or more base pairs 
length difference), we marked the locus in blue and scored the two alleles 
independently. Unambiguous loss of heterozygosity is highlighted with a blue 
background and not counted as a poly-G mutation. The sample description from the 
surgical pathology report is given along with the name of the sample. Samples appear 
in the same order as in the corresponding heatmap.
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Table S4: Genotyping information for all samples collected from patient C13. Poly-
G loci are listed in the rows of the table (Sal104-Sal21). Deletions are recorded as 
m[number of deleted bases] and marked in red, insertions as p[number of inserted 
bases] and marked in orange. The sample description from the surgical pathology 
report is given along with the name of the sample. Samples appear in the same order 
as in the corresponding heatmap.
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Table S5: Genotyping information for all samples collected from patient C31. Poly-
G loci are listed in the rows of the table (Sal104-Sal21). Deletions are recorded as 
m[number of deleted bases] and marked in red, insertions as p[number of inserted 
bases] and marked in orange. If a locus was clearly heterozygous (6 or more base pairs 
length difference), we marked the locus in blue and scored the two alleles 
independently. The sample description from the surgical pathology report is given along 
with the name of the sample. Samples appear in the same order as in the 
corresponding heatmap. 
 120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Sa
m
pl
e'
de
sc
rip
tio
n'
fr
om
'
su
rg
ic
al
'
pa
th
ol
og
y'
re
po
rt
Ap
pe
nd
ix
Po
ly
p
Co
lo
n-
m
as
s
Co
lo
n-
m
as
s
Co
lo
n-
m
as
s
Co
lo
n-
m
as
s
M
at
te
d-
ly
m
ph
-n
od
e-
m
as
s-
ab
ut
tin
g-
m
es
en
te
ric
-
m
ar
gi
n
M
at
te
d-
ly
m
ph
-n
od
e-
m
as
s-
ab
ut
tin
g-
m
es
en
te
ric
-
m
ar
gi
n
Ri
gh
t-o
va
ry
-
an
d-
fa
llo
pi
an
-
tu
be
,-m
as
s
Ri
gh
t-o
va
ry
-
an
d-
fa
llo
pi
an
-
tu
be
,-m
as
s
Ri
gh
t-o
va
ry
-
an
d-
fa
llo
pi
an
-
tu
be
,-m
as
s
Ri
gh
t-o
va
ry
-
an
d-
fa
llo
pi
an
-
tu
be
,-m
as
s
Ri
gh
t-o
va
ry
-
an
d-
fa
llo
pi
an
-
tu
be
,-m
as
s
Ri
gh
t-o
va
ry
-
an
d-
fa
llo
pi
an
-
tu
be
,-m
as
s
Ri
gh
t-o
va
ry
-
an
d-
fa
llo
pi
an
-
tu
be
,-m
as
s
Ri
gh
t-o
va
ry
-
an
d-
fa
llo
pi
an
-
tu
be
,-m
as
s
N
Po
ly
p
PT
4
PT
2
PT
1
PT
3
LN
1
LN
2
RO
1
RO
5
RO
2
RO
8
RO
7
RO
6
RO
3
RO
4
1
Sa
l1
04
12
7R
H
12
7R
H
m
1
m
1
m
1
m
1
m
1
m
1
m
2
m
2
m
2
m
2
m
2
m
2
m
2
m
2
2
Sa
l1
02
15
6L
H
15
6L
H
15
6L
H
15
6L
H
15
6L
H
15
6L
H
15
6L
H
15
6L
H
15
6L
H
m
1
m
1
15
6L
H
15
6L
H
15
6L
H
15
6L
H
15
6L
H
3
Sa
l8
7
20
0R
H
20
0R
H
m
1
m
1
m
1
m
1
m
1
m
1
m
1
m
1
m
1
m
1
m
1
m
1
m
1
m
1
4
Sa
l8
4
19
9
19
9
19
9
19
9
19
9
19
9
19
9
19
9
19
9
19
9
19
9
19
9
19
9
19
9
19
9
19
9
5
Sa
l8
3
20
9/
21
0
20
9/
21
0
m
1
m
1
m
1
m
1
m
1
m
1
m
2
m
2
m
2
m
2
m
2
m
2
m
2
m
2
6
Sa
l7
8
18
2
18
2
18
2
18
2
18
2
18
2
18
2
18
2
18
2
18
2
18
2
18
2
18
2
18
2
18
2
18
2
7
Sa
l7
4
18
9
18
9
18
9
18
9
18
9
18
9
18
9
18
9
18
9
18
9
18
9
18
9
18
9
18
9
18
9
18
9
8
Sa
l6
6
17
7/
17
8
17
7/
17
8
17
7/
17
8
17
7/
17
8
17
7/
17
8
17
7/
17
8
17
7/
17
8
17
7/
17
8
17
7/
17
8
17
7/
17
8
17
7/
17
8
17
7/
17
8
17
7/
17
8
17
7/
17
8
17
7/
17
8
17
7/
17
8
9
Sa
l5
7
20
1/
20
2
20
1/
20
2
m
1
m
1
m
1
m
1
m
1
m
1
m
1.
5
m
1
m
1.
5
m
1.
5
m
1.
5
m
1.
5
m
1.
5
m
1.
5
10
Sa
l5
4
16
6/
16
7
16
6/
16
7
16
6/
16
7
16
6/
16
7
16
6/
16
7
16
6/
16
7
16
6/
16
7
16
6/
16
7
16
6/
16
7
16
6/
16
7
16
6/
16
7
16
6/
16
7
16
6/
16
7
16
6/
16
7
16
6/
16
7
16
6/
16
7
11
Sa
l5
2
18
0
18
0
18
0
18
0
18
0
18
0
18
0
18
0
18
0
18
0
18
0
18
0
18
0
18
0
18
0
18
0
12
Sa
l4
7
17
9
17
9
17
9
17
9
17
9
17
9
17
9
17
9
17
9
17
9
N
A
17
9
17
9
17
9
17
9
17
9
13
Sa
l4
6
16
3
16
3
16
3
16
3
16
3
16
3
16
3
16
3
16
3
16
3
16
3
16
3
16
3
16
3
16
3
16
3
14
Sa
l4
1
17
5
m
1
m
1
m
1
m
1.
5
m
1.
5
m
1
m
1
m
1.
5
m
1.
5
m
1.
5
m
1.
5
m
1.
5
m
1.
5
m
1.
5
m
1.
5
15
Sa
l3
6
11
3/
12
1
11
3/
12
1
11
3/
m
1
11
3/
12
1
11
3/
12
1
11
3/
12
1
11
3/
12
1
11
3/
12
1
11
3/
12
1
11
3/
12
1
11
3/
12
1
11
3/
12
1
11
3/
12
1
11
3/
12
1
11
3/
12
1
11
3/
12
1
16
Sa
l3
0
11
7
11
7
11
7
11
7
11
7
11
7
11
7
11
7
11
7
11
7
11
7
11
7
11
7
11
7
11
7
11
7
17
Sa
l2
6
15
8
m
1
15
8
m
1
m
1
15
8
15
8
15
8
m
1
m
1
m
1
15
8
m
1
m
1
m
1
m
1
18
Sa
l2
2M
U
A
19
0
19
0
19
0
19
0
19
0
19
0
19
0
19
0
19
0
19
0
19
0
19
0
19
0
19
0
19
0
19
0
19
Sa
l2
2M
LA
17
9
17
9
17
9
17
9
17
9
17
9
17
9
17
9
17
9
17
9
17
9
p0
.5
p0
.5
p0
.5
p0
.5
p0
.5
20
Sa
l2
1
15
2/
15
5
15
2/
15
5
m
1.
5/
15
5
15
2/
m
1
15
2/
m
1
15
2/
m
1
15
2/
15
5
15
2/
m
1
15
2/
m
1
15
2/
m
1
15
2/
m
1
m
1/
15
5
15
2/
m
1
m
1/
15
5
m
1/
15
5
m
1/
15
5
Ta
bl
e 
S5
 (C
on
tin
ue
d)
. 
 121 
Table S6: Genotyping information for all samples collected from patient C27. Poly-
G loci are listed in the rows of the table (Sal104-Sal21). Deletions are recorded as 
m[number of deleted bases] and marked in red, insertions as p[number of inserted 
bases] and marked in orange. If a locus was clearly heterozygous (6 or more base pairs 
length difference), we scored the two alleles independently. UA - Upper allele, LA – 
Lower allele. The sample description from the surgical pathology report is given along 
with the name of the sample. Samples appear in the same order as in the 
corresponding heatmap.
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Table S7: Genotyping information for all samples collected from patient O1. Poly-
G loci are listed in the rows of the table (Sal104-Sal21). Deletions are recorded as 
m[number of deleted bases] and marked in red, insertions as p[number of inserted 
bases] and marked in orange. Unambiguous loss of heterozygosity is highlighted with a 
blue background and not counted as a poly-G mutation. The sample description from 
the surgical pathology report is given along with the name of the sample. 
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Table S8: Genotyping information for all samples collected from patient B1. Poly-
G loci are listed in the rows of the table (Sal104-Sal21). Deletions are recorded as 
m[number of deleted bases] and marked in red, insertions as p[number of inserted 
bases] and marked in orange. Unambiguous loss of heterozygosity is highlighted with a 
blue background and not counted as a poly-G mutation. The sample description from 
the surgical pathology report is given along with the name of the sample. 
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Table S9: Genotyping information for all samples collected from a renal cell 
carcinoma. Poly-G loci are listed in the rows of the table (Sal104-Sal21). Deletions are 
recorded as m[number of deleted bases] and marked in red, insertions as p[number of 
inserted bases] and marked in orange. Unambiguous loss of heterozygosity is 
highlighted with a blue/purple background and not counted as a poly-G mutation. The 
sample description from the surgical pathology report is given along with the name of 
the sample 
 
 
 
 
  
 128 
Table S10: Genotyping information for various other tumor types. Poly-G loci are 
listed in the rows of the table (Sal104-Sal21). Deletions are recorded as m[number of 
deleted bases] and marked in red, insertions as p[number of inserted bases] and 
marked in orange. Unambiguous loss of heterozygosity is highlighted with a blue/purple 
background and not counted as a poly-G mutation. 
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Appendix B – Protocols and primer sequences 
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Protocol for DNA extraction & precipitation from FFPE tissue blocks  
1. Punch specimen with a 1.5 mm or 2 mm biopsy punch 
2. (Wash punch in 100% ethanol and wipe to re-use, optional) 
3. (Cut core in smaller pieces with scalpel, optional) 
4. Add 1 ml xylene and incubate at 56°C for up to 30 min 
5. Centrifuge and discard xylene 
6. (Repeat, optional) 
7. Wash the pellet twice with 100% ethanol 
8. Air dry the pellet 
9. Add 784 µl Shibata buffer (100 mM TrisHCl, pH 8; 4 mM EDTA, pH 8) to each 
sample  
10.  Add 16 µl Proteinase K to each sample 
11.  Incubate overnight (or longer) at 56°C until all tissue is dissolved, adding 
Proteinase K as needed 
12.  Let sample cool to room temperature (RT), add equal volume Phenol : 
Chloroform : IAA (25:25:1, pH 8, RT) 
13.  Vortex for 1 minute 
14.  Centrifuge at 14000 rpm for at least 5 minutes at RT. 
15.  Retrieve aqueous phase, note precise volume 
16. Add 1/10 volume 3M Sodium Acetate 
17.  Add 2.5 volumes 100% ethanol 
18.  Add 1-2 µl glycogen 
19.  Precipitate overnight at -80°C 
 131 
20.  Centrifuge at 4°C for 45 min 
21.  Wash DNA pellet with 1 ml ice-cold 70% ethanol. Pipet up and down to make 
sure pellet is properly immersed. 
22.  Incubate at -80°C for one hour 
23.  Centrifuge at 14000 rpm for 1 minute at 4°C. 
24.  Repeat step 9 and 10 
25.  Air dry pellet 
26.  Resuspend in at least 50 µl nuclease-free water 
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Primer sequences for amplification of poly-G loci 
 
These sequences have been previously published in: 
Salk, J. J., Salipante, S. J., Risques, R. A., Crispin, D. A., Li, L., Bronner, M. P., et al. 
(2009). Clonal expansions in ulcerative colitis identify patients with neoplasia. 
Proceedings of the National Academy of Sciences, 106(49), 20871–20876. 
doi:10.1073/pnas.0909428106 
 
 
 
 
Locus ID Chr Forward primer 5'->3' Reverse primer 5' -> 3' Exp. size Comments
Sal102 2 ttggtattctattatagcagcctgaac GTTTCTTcattacacatacttattaccaccaggac 153 intergenic
Sal103 2 gggcagtattaaaaactatagaatacccGTTTCTTtacactcttgtgcattttccttttc 168 intergenic
Sal104 1 agttacgacaatcaaaaatgtctctg GTTTCTTgagatgcctagaccactgattctc 129 MTR intron
Sal105 1 ttaccttaacattcagtcttcctcttg GTTTCTTtagatatgccacttttgtcatctacag 167 ENAH & PARP1 intron
Sal107 1 ctctcatgacctagctaaaaatgattc GTTTCTTgcccagacttttatttcttattttgtc 114 PLD5 intron
Sal2 X tcatcaggttactaggcaatattagg GTTTCTTctctgtccctgaccaggtctac 108 MAGED4B intron
Sal21 17 tacccaggtgtaagatcttgaaaag GTTTCTTaggaaacctctactcatgctgaaag 143 GPATCH8 intron
Sal22 17 cctatattcccagctacagctacac GTTTCTTgggtatatagtgatagtggtttgtttc 188 GPATCH8 intron
Sal26 16 gactgacactgttgtaataccaagg GTTTCTTggtttcaaacattacaagatcaagg 154 intergenic
Sal27 16 ctgatgagggacaggaatctcac GTTTCTTatgacccagggacaggtacag 101 intergenic
Sal30 15 ggagtattgctaggagggagttttc GTTTCTTcgctatatgggtagtcactatctgg 112 intergenic
Sal36 14 gggcattcaggaccactagg GTTTCTTgttcagagcgtctcttggtttc 125 abPARTs intron
Sal41 13 tcttttgactctaagtcccttagcc GTTTCTTgtttatagtccgctttttgtaaagg 173 intergenic
Sal45 12 aaggtctgagataagctccagaatc GTTTCTTaccttagagttcggtgtcatgaag 125 ANO6 intron
Sal46 12 ccgttattaaaaagtctcacgtttg GTTTCTTatatctaacctctcctcaggtttcc 156 SPATS2 intron
Sal47 12 tttggttaaggccctaaatttgaac GTTTCTTtttctgcatttttatagtgctttcc 175 intergenic
Sal52 11 cagctaatttttctgtttttagtacagg GTTTCTTtgcagtcaagaacccatcac 175 TCIRG1 intron
Sal54 10 ctaagtgttaaggacacagactgaagg GTTTCTTgagaccttacaggaacagaagaatatc 161 CXCL12 intron
Sal57 10 ccgaatcttaaattgaaaacacaaag GTTTCTTtttttagtagaaatggggtttcacc 199 intergenic
Sal58 10 gtaagtaaatcaatgaatgtggttgtg GTTTCTTataaatttttattggattttcgtttgg 113 intergenic
Sal64 9 gtaatcaccatcaatttggcaatttac GTTTCTTgactaagggaggagaatcactagaac 162 RNF38 intron
Sal66 8 acatgtacattcagttcactgttaagc GTTTCTTtagctttgttctagttttgtgtgtgtg 171 intergenic
Sal74 7 taacaagggaatgtaaaggaacttatg GTTTCTTttatttagtccagatttaatgacaaagg 183 intergenic
Sal75 7 catgagttcaattgtttttatttttagc GTTTCTTcatttctgagataagggttcaaatg 181 intergenic
Sal78 7 caaagagtgaaacagactatcgacttc GTTTCTTaacctttagatttacagaaaaattgagc 175 intergenic
Sal81 6 gtgaactgtgtttctgtcactacactc GTTTCTTtacaaaaatcatggtttagttttctcc 158 RANBP9 intron
Sal83 6 cagtgtctcattcatctttgtcattc GTTTCTTcaaaaactacaaaatgtcttaatggag 200 JARID2 intron
Sal84 6 aggtgtctgagaataaagaagatgaagGTTTCTTatggattcctggtgagatgttg 195 intergenic
Sal87 4 tacatgaaattctcaatgattacaacg GTTTCTTaagatctattccatcccattgactc 197 ARHGAP10 intron
Sal88 4 aattttcagtctctgagtgtgatcc GTTTCTTcatttgcgagcaatttctctttag 187 WWC2 intron
